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ABSTRACT
Smoking cigarettes is the most preventable cause of death in the US. Smokers are
often unsuccessful at quitting because they are dependent. Reducing nicotine could be one
way to reduce dependence. Currently, reducing cigarettes per day (CPD) is the most
common strategy to reduce nicotine intake. However, some have proposed switching to
very low nicotine content (VLNC) cigarettes to reduce nicotine and dependence. Both
reducing CPD and switching to VLNC cigarettes aim to reduce nicotine but do so in
different ways. I conducted a randomized trial to compare the degree to which switching
to VLNC cigarettes vs reducing CPD 1) is more acceptable and 2) decreases dependence
more among smokers not ready to quit.
Sixty-eight adult smokers of ≥ 10 cigarettes/day who were not ready to quit smoked
full nicotine study cigarettes ad-lib for 1 week (week 0). I provided all participants with
nicotine replacement therapy (NRT) patches and instructions to gradually reduce over the
next 4 weeks by either 1) switching to lower nicotine content VLNC cigarettes or 2)
reducing the number of full nicotine CPD. I provided VLNC participants with their usual
number of cigarettes throughout the study but cigarettes contained only 70% of their usual
nicotine at week 1, 35% at week 2, 15% at week 3, and 3% at week 4. I provided CPD
participants with full nicotine cigarettes throughout the study but only 70% of their usual
number of cigarettes at week 1, 35% at week 2, 15% at week 3, and 3% at week 4. I
instructed participants to attempt to smoke only study cigarettes and report use of all (study
+ non-study) cigarettes via nightly surveys. I used participants’ percent non-study
cigarettes/day as a proxy for acceptability and the Nicotine Dependence Syndrome Scale
as my primary measure of dependence. Participants completed self-report measures and
provided breath and urine samples at weekly visits during the 5-week study period. I tested
between-group differences, within-participant change over time, and group by time
interactions using multi-level modeling.
Switching to VLNC cigarettes was more acceptable than reducing CPD (F=5.0
p<.05). Acceptability declined over time for CPD participants as they were instructed to
reduce more nicotine (F=42.2, p<.001) but this was not true for VLNC participants
(F=29.5, p<.001). Dependence declined over time for both VLNC (F=10.5, p<001) and
CPD (F=5.0, p<.01) participants but declined more over time for VLNC than CPD
participants (F=3.2, p<.05).
This is the first trial to directly compare switching to VLNC cigarettes vs reducing
CPD. Large reductions were more acceptable and effective at decreasing dependence
among participants who switched to VLNC cigarettes than those who reduced CPD when
all were aided by NRT. My findings suggest that regulatory policy that promotes a gradual
transition to VLNC cigarettes could be more acceptable and effective at decreasing
dependence than the common strategy of reducing CPD. Furthermore, NRT-aided
transitions to VLNC cigarettes could be a useful and acceptable component for clinical
interventions to reduce nicotine dependence among smokers not ready to quit and thereby
make it more likely for smokers to quit and succeed.
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CHAPTER 1: INTRODUCTION
1.1. Background
Smoking is associated with over 480,000 deaths per year in the United States (US
Department of Health and Human Services, 2014). Though the prevalence of smoking
has declined dramatically since 1964, it has slowed to less than 1% per year since 1990
(US Department of Health and Human Services, 2014). Currently, only 5% of smokers
quit each year (Bondy et al., 2013; Weinberger, Pilver, Mazure, & McKee, 2014) and
most are not ready to quit in the near future (PROPEL Centre for Population Health
Impact, 2015). Smokers who are more dependent are less likely to quit (US Department
of Health and Human Services, 2014). Reducing smokers’ nicotine intakes may be one
way to reduce dependence (Benowitz et al., 2009; Benowitz et al., 2007; Donny et al.,
2015). Presently, reducing cigarettes per day (CPD) is the most common strategy to
reduce nicotine intake (Beard, Fidler, & West, 2011; PROPEL Centre for Population
Health Impact, 2015; West & Brown, 2012). Another proposed method to reduce
smokers’ nicotine intake and dependence is to switch to very low nicotine content
(VLNC) cigarettes (Benowitz & Henningfield, 1994; Hatsukami et al., 2010). In contrast
to traditional “light” cigarettes (Benowitz et al., 2005), VLNC cigarettes contain tobacco
with reduced nicotine content and result in minimal compensatory smoking (Hatsukami,
Donny, Koopmeiners, & Benowitz, 2015).
It is unclear whether switching to VLNC cigarettes or reducing CPD is 1) more
acceptable and 2) more effective at decreasing dependence. Though both methods aim to
reduce nicotine intake, switching to VLNC cigarettes and reducing CPD may work in
1

different ways. Individuals smoke cigarettes in response to cues (i.e., Pavlovian
conditioning) and to obtain unconditioned (nicotine) and conditioned (smoking
sensations) rewards (i.e., operant conditioning; (Conklin & Tiffany, 2002; Russell,
1971)). Both appear to influence cigarette enjoyment (i.e., subjective effects) and
dependence (Rose, Behm, Westman, & Johnson, 2000; Rose & Levin, 1991).
Switching to VLNC cigarettes reduces the magnitude of the unconditioned
reinforcer (nicotine) without changing conditioned reinforcers (smoking sensations) or
restricting smoking behavior in responses to environmental or internal cues to smoke
(Figure 1). There are multiple ways in which this could decrease dependence. First,
smoking with minimal nicotine as a reinforcer could disrupt associations between
smoking behavior and unconditioned reinforcement (path b). Second responding to
environmental or internal cues by smoking cigarettes with minimal unconditioned
reinforcement (nicotine) could disrupt the association between cues to smoke and
smoking behavior (path a). Finally, experiencing smoking sensations with minimal
nicotine could disrupt associations between conditioned and unconditioned reinforcers
(path d).

Figure 1: Switching to very low nicotine content (VLNC) cigarettes.

2

Reducing CPD restricts the pattern and frequency of smoking behavior
(cigarette/day) without changing unconditioned (nicotine) or conditioned (smoking
sensations) reinforcers (Figure 2). This could decrease dependence by providing
increased opportunity to practice not smoking in the presence of environmental or
internal cues to smoke (path a). Further an overall reduction in the frequency of
unconditioned (nicotine; path b) and conditioned (smoking sensation; path c) reinforcers
could contribute to decreased dependence.

Figure 2: Reducing cigarettes per day (CPD).

I conducted a randomized trial to compare the extent to which switching to VLNC
cigarettes vs reducing CPD 1) is acceptable and 2) decreases dependence among daily
smokers who do not want to quit. I had no hypotheses as to whether switching to VLNC
cigarettes or reducing CPD would be more acceptable or decrease dependence more
because this is an initial test of strategies that both appear effective and I am equally
interested in effects in either direction.
Smokers who reduce CPD usually reduce gradually. Though it is unclear how the
FDA will introduce nicotine regulation, gradual transitions to VLNC cigarettes has been
proposed (Benowitz & Henningfield, 1994; Hatsukami et al., 2015). Therefore I tested
gradual transition to VLNC cigarettes vs gradual reductions in CPD.
3

1.1.1. Switching to Very Low Nicotine Content (VLNC) Cigarettes
I searched PubMed, Medline, Cochrane and my personal library for relevant
literature. In addition, I examined articles that referenced or were referenced by relevant
studies. Below is a review of the effect of gradual transitions to VLNC cigarettes on
compliance (i.e., using only VLNC cigarettes) and dependence in the five published trials
that I located. Compliance with VLNC cigarettes has been used as a measure
acceptability (Mercincavage et al., 2017). Many of the studies report on the Fagerstrom
Test for Cigarette Dependence (FTCD). Importantly, this measure can be administered
with or without a measure of cigarettes/day. The studies below report on FTCD with
cigarettes/day unless otherwise stated. Participants in all five studies were adult daily
smokers who were not ready to quit in the near future. See Table 1 for a summary of
studies on gradual transitions to VLNC cigarettes.
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Table 1: Trials of gradual transition to very low nicotine content (VLNC) cigarettes.
Author,
Year

N

Benowitz,
2007

21

Benowitz,
2009

20

Benowitz,
2012

135

Hammond,
2014

101

VLNC cigarettes
Weekly taper from UB to 12
mg, 8 mg, 4 mg, 2 mg and 1
mg nicotine content cigarettes.
Weekly taper from UB to
approximately 16.5 mg, 11.3
mg, 6.0 mg, 5.5 mg, and 2.5
mg nicotine content cigarettes.
Monthly taper from UB to 10.3
mg, 8.5 mg, 3.9 mg, and 1.7
mg nicotine content cigarettes
followed by 6 months of a 0.5
mg nicotine content cigarette.
Weekly taper from UB to 8.9
mg, 8.6 mg, and 0.6 mg
nicotine content cigarettes

Taper
duration

Compliance to study cigarettes

Dependence

42 days

Not reported

Significant decrease in FTCD
from baseline to the 70-day
follow-up.

42 days

Not reported

Significant decrease in FTCD
from the end of the taper to the
70-day follow-up.

a

365 days

40-60% smoked some non-study
cigarettes

b

28 days

28-44% smoked some non-study
cigarettes

5

c

Significant decrease in FTCD
when smoking < 3.9 mg
nicotine content cigarettes.
Significant decrease in NDSS
stereotypy subscale only from
baseline to the end of the 28day taper.

Participants who smoked any nonstudy cigarettes were removed from the
Mercincavage,
study. There was 25% overall attrition,
123
35 days
Not reported
2016
8% when smoking 8.9 mg cigarettes,
9% for 5.1 mg cigarettes, and 18% for
1.5 mg nicotine cigarettes.
a
Biochemical estimation of compliance to 0.5 mg nicotine content cigarettes over a 6-month period in a secondary analysis (Benowitz, Nardone,
Hatsukami, & Donny, 2015); bParticipants’ self-report throughout the 4-week taper; cCompliance reported in a separate publication (Mercincavage et
al., 2017). FTCD=Fagerstrom test for cigarette dependence (Fagerstrom, 2012); mg=Milligram; NDSS=Nicotine dependence syndrome scale (Shiffman,
Waters, & Hickcox, 2004); UB=Usual brand; VLNC=Very low nicotine content.
Five days of ad-lib UB
smoking followed by a taper in
three 10-day periods: 8.9 mg,
5.1 mg, and 1.5 mg of nicotine
per cigarette.

One observational trial instructed 21 participants to smoke their usual brand
cigarettes during the first week and then progressively reduce to VLNC research
cigarettes containing 12 mg, 8 mg, 4 mg, 2 mg, and 1 mg of nicotine each week over the
next 5 weeks (Benowitz et al., 2007). Participants were then followed for 1 month after
returning to their usual brand cigarettes or quitting. Five participants quit smoking and
mean FTCD scores (1=least and 10=most dependence) (Fagerstrom, 2012) of the
remaining smokers decreased from 4.3 at baseline to 3.6 at week 6 (p=.09) to 2.5 at week
10 (p<.001). The FTCD contains an item regarding cigarettes/day and thus is influenced
by changes in the number of cigarettes smoked. Cigarettes/day decreased nonsignificantly from baseline (19 cigarettes/day) to week 6 (18 cigarettes/day) and
significantly from week 6 to week 10 (10 cigarettes/day) after participants had returned to
their usual brand cigarettes. Though compliance with using only VLNC cigarettes (i.e.,
not using usual brand cigarettes) was not reported, only one participant withdrew from
the study. Cotinine progressively decreased with lower nicotine cigarettes. Cotinine
increased at follow-up though remained lower than baseline. Compared to baseline, selfefficacy to quit was higher after the taper and at follow-up and 5 participants quit after
the taper. Thus, a relatively short (6-week) taper from full nicotine to 1-mg nicotine
content cigarettes appears to affect participants’ dependence, cotinine, and self-efficacy
to quit but not their cigarettes/day when smoking VLNC cigarettes.
A similar trial instructed 20 participants to smoke their usual brand cigarettes
during the first week and then progressively reduce to commercially available cigarettes
with approximately 16.5 mg, 11.3 mg, 6.0 mg, 5.5 mg, and 2.5 mg nicotine content over
6

the next 5 weeks (Benowitz et al., 2009). Dependence changed from a mean 3.9 FTCD
score at baseline to 4.1 at week 6 to 3.3 at week 10. The change from baseline to week 6
was not significant, but baseline to week 10 was significant. Cigarettes/day increased
non-significantly from baseline (19 cigarettes/day) to week 6 (22 cigarettes/day) and
decreased significantly from week 6 to week 10 (15 cigarettes/day) when participants
returned to their usual brand cigarettes. Compliance was not reported but all 20
participants completed the study. Cotinine was stable during weeks 1 to 4 but decreased
during weeks 5 and 6. Cotinine increased at follow-up but remained lower than baseline.
Compared to baseline, self-efficacy to quit was higher after the taper and at follow-up
and 2 participants quit after the taper. Thus, this trial replicates previous findings
(Benowitz et al., 2007) that a taper to VLNC cigarettes is associated with reduced
dependence and cotinine and increased self-efficacy to quit.
In another observation trial 101 smokers who were not ready to quit in the next
month were instructed to gradually transition to VLNC cigarettes over 4 weeks
(Hammond & O'Connor, 2014). They initially smoked usual brand cigarettes for 1 week
and then progressively reduced to 8.9 mg, 8.6 mg, and 0.6 mg nicotine content cigarettes
for 1 week each for the next three weeks. This trial utilized the only VLNC cigarettes that
were commercially available at the time of the study and thus had a large and abrupt
reduction in nicotine content from week 3 to week 4 (8.6 mg to 0.6 mg). There was a
non-significant decrease in dependence from a mean 4.9 FTCD score at week 1 to a mean
4.4 FTCD score at week 4. There was also a significant decrease in the NDSS stereotypy
(invariance of smoking) subscale raw scores (-5=least and 5=most dependence)
(Shiffman et al., 2004) from a mean of 3.7 at week 1 (when smoking usual brand
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cigarettes) to 3.4 at week 4 (when smoking 0.6 mg nicotine content cigarettes), but
decreases in the NDSS total and 4 other subscale scores were non-significant. There were
no changes in the number of VLNC cigarettes/day across the 4-week study. In contrast to
the FTCD, the NDSS is not influenced by changes in cigarettes/day. Twenty eight
percent of participants did not complete the taper. In addition the proportion of
participants that reported smoking any non-study cigarettes was 28% during week 2 (8.9
mg cigarette), 31% during week 3 (8.6 mg cigarette), and 44% during week 4 (0.6 mg
cigarette). Cotinine progressively decreased with lower nicotine cigarettes and there was
no change in CO. This brief and relatively abrupt transition to VLNC cigarettes had a
decrease in a stereotypy subscale of dependence, decreased cotinine, no effect on
cigarettes/day or CO, and low compliance.
A larger and more recent randomized controlled trial (RCT) (Benowitz et al.,
2012) used a sample of 135 participants. The VLNC group smoked their usual brand
cigarettes for two weeks and then progressively reduced to 10.3 mg, 8.5 mg, 3.9 mg, and
1.7 mg nicotine content cigarettes for 4 weeks each. Participants then smoked 0.5 mg
nicotine content cigarettes for the next 6 months and were followed for a year after
returning to usual brand cigarettes. The control group smoked usual brand cigarettes as
usual for the same amount of time. Change was measured from baseline to weeks 14 and
26 and compared between groups. Two participants in the VLNC and one in the control
condition quit smoking by the end of the 26-week taper. Dependence changed from an
FTCD score of 5.6 at baseline (when smoking usual brand cigarettes) to an FTCD score
of 5.7 at week 14 (when smoking 1.7 mg cigarettes) to an FTCD score of 5.3 at week 26
(when smoking 0.5 mg cigarettes). Change from baseline to week 26 was not significant
8

but change from week 14 to 26 was. This decrease was significantly greater than the
change in FTCD in the control group. In the VLNC group, cigarettes/day did not change
during the first 14 weeks but reduced significantly from 24 cigarettes/day at week 14 to
20 cigarettes/day at week 26 when participants switched from cigarettes containing 1.7 to
0.5 mg of nicotine. Ten percent of participants in the control and 11% in the VLNC group
withdrew and 21% of participants in the VLNC group reported some non-compliance;
i.e., smoking some usual brand cigarettes during the taper to VLNC cigarettes. However,
a secondary analysis exploring biochemical verification of compliance concluded that a
much higher proportion of participants (40-60%) were non-compliant during the final 6month period when they were instructed to smoke 0.5 mg nicotine content cigarettes
(Benowitz et al., 2015). This is the only study that used biochemical testing to estimate
compliance with switching to VLNC cigarettes. Cotinine remained stable until week 14
(1.7 mg cigarettes) and then declined by 44% by week 26 (0.5 mg cigarettes). Carbon
monoxide (CO) increased by a mean 4 ppm. There was no change in self-efficacy and 2
participants quit smoking after the taper. Thus, a 26-week taper to VLNC cigarettes
appeared to decrease dependence, cotinine, CO, and cigarettes/day but only when
participants reduced to the lowest nicotine content cigarettes despite relatively low
compliance (Benowitz et al., 2012).
In a recent trial of 123 smokers not ready to quit (Mercincavage et al., 2016),
participants were randomized to either smoke their usual brand cigarettes throughout the
35 day study period or progressively switch to VLNC cigarettes. Participants who
switched to VLNC cigarettes began with 5 days of ad-lib usual brand cigarettes and then
three 10-day periods of cigarettes containing 8.9 mg, 5.1 mg, and 1.5 mg nicotine.
9

Participants were removed from the study if they reported smoking any non-study
cigarettes. In a secondary analysis, the authors examined attrition as a proxy for
acceptability (Mercincavage et al., 2017) and found that, there was 25% overall attrition.
Attrition was significantly greater in the VLNC vs control conditions and increased as the
nicotine content of cigarettes decreased; i.e., 8% when smoking 8.9 mg cigarettes, 9% for
5.1 mg cigarettes, and 18% for 1.5 mg nicotine cigarettes. Cotinine progressively
decreased with lower nicotine cigarettes and CO increased when participants switched to
5.1 mg cigarettes. The authors did not report on changes in dependence.
In summary, a gradual transition to VLNC cigarettes appears to vary in
acceptability but have positive effects on dependence in smokers who are not ready to
quit. Three of five trials measured compliance to study cigarettes and estimated that 2560% of participants smoked some usual brand cigarettes during their taper to VLNC
cigarettes (Benowitz et al., 2015; Hammond & O'Connor, 2014; Mercincavage et al.,
2017). All four trials that measured dependence found that switching to VLNC cigarettes
is associated with a reduction in dependence. Two trials found decreases in dependence
scores from baseline to follow-ups after a taper to VLNC cigarettes (Benowitz et al.,
2007; Hammond & O'Connor, 2014). One found a decrease in dependence at lower levels
of VLNC cigarettes (Benowitz et al., 2012) and the other found a decrease in dependence
from the end of the taper to VLNC cigarettes to a 10 week follow-up (Benowitz et al.,
2009). However, it is unclear whether reductions in dependence (5-42%) were clinically
significant. Three trials found no change in cigarettes/day while participants were
smoking VLNC cigarettes but still showed some reduction in dependence (Benowitz et
al., 2009; Benowitz et al., 2007; Hammond & O'Connor, 2014). Thus it appears that,
10

despite low compliance, gradually switching to VLNC cigarettes decreases dependence
but not cigarettes/day in most previous trials.
1.1.2. Reducing Cigarettes per Day (CPD)
Despite a large body of literature on reducing CPD in smokers not trying to quit
(Hughes & Carpenter, 2005; Wu, Sun, He, & Zeng, 2015), few studies report on
reduction’s effect on dependence or the acceptability of reducing CPD. I reviewed
compliance with instructions to reduce CPD as an indication of acceptability. Most
reduction trials did not provide a goal to reduce a specific proportion of CPD and thus
could not measure compliance. Below I summarize reduction’s effect on dependence as
well as the extent to which smokers are able to reduce and the few trials that report
compliance with instructions to reduce a specified proportion of CPD (i.e., achieve
reduction goals).
I searched PubMed, Medline, Cochrane, and my personal library. In addition, I
examined articles that referenced or were referenced by relevant studies. I identified six
reviews and meta-analyses on reducing CPD among smokers who are not ready to quit
(Asfar, Ebbert, Klesges, & Relyea, 2011; Hughes, 2000; Hughes & Carpenter, 2005,
2006; Moore et al., 2009; Wu et al., 2015) and four studies that reported on the
association between reducing CPD and dependence (Etter, Laszlo, Zellweger, Perrot, &
Perneger, 2002; Fagerstrom, Hughes, & Callas, 2002; Klemperer, Hughes, & Callas,
2015; Mooney, Johnson, Breslau, Bierut, & Hatsukami, 2011). See Table 2 for a
summary of studies that reported on the association between reducing CPD and
dependence.
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There is a large body of literature regarding reducing CPD. Two of the six
identified reviews reported on the extent to which smokers reduced CPD but neither
addressed participants’ compliance with assigned reduction goals (Hughes, 2000; Hughes
& Carpenter, 2005). The first review identified 5 trials of NRT-aided reduction
interventions for smokers who are not ready to quit (Hughes, 2000). The interventions
achieved 30-63% reductions in CPD at 1-6 month follow-ups. Another review examined
naturalistic and experimental studies of reduction and determined that, while most
smokers decrease CPD slightly over time, few achieve substantial reductions (i.e., >
50%) on their own (Hughes & Carpenter, 2005). The review identified 19 trials of NRTaided reduction interventions. The trials provided participants with NRT gum or inhaler
or a choice of NRTs. Five trials’ longest follow-ups were at 1 to 5 months and 14 trials’
longest follow-ups were at 6 to 26 months. One trial reported a small mean reduction
(6%), nine reported a moderate reduction (18-45%), and 4 reported a large reduction (5375%) in CPD within the reduction conditions.
A limited number of studies report on smokers’ compliance with instructions to
reduce CPD. I examined the 23 trials that were included in the 6 identified meta-analyses
and reviews on interventions to reduce CPD (Asfar et al., 2011; Hughes, 2000; Hughes &
Carpenter, 2005, 2006; Moore et al., 2009; Wu et al., 2015). Ten trials gave participants
explicit goals to reduce their CPD and thus were able to measure compliance. All
provided medication to aid reduction and 6 provided counseling. Treatment duration
ranged from 4 to 72 weeks (Carpenter, Hughes, & Keely, 2003; Ebbert et al., 2015; Etter
et al., 2002; Hatsukami et al., 2004; Hecht et al., 2004; Hurt et al., 2000; Joseph et al.,
2008; Rennard et al., 1990; Riley, Jerome, Behar, & Weil, 2002; Stein et al., 2002). Six
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trials instructed participants to reduce by ≥50% by the end of treatment. Four of the six
found that 25-39% of participants complied with the goal to reduce 50% of their CPD
over 4 to 26 weeks (Carpenter et al., 2003; Etter et al., 2002; Hatsukami et al., 2004;
Riley et al., 2002). Two of the six trials did not report the proportion of participants that
were compliant but found that participants reduced a mean of 36% of their baseline CPD
over 72 weeks (Joseph et al., 2008) and 63% over 8 weeks (Rennard et al., 1990). Three
trials instructed participants to reduce by 75% by the end of treatment. One reported 26%
compliance over 8 weeks (Ebbert et al., 2015), the second reported 9% compliance over
12 weeks (Hurt et al., 2000), and the third did not report compliance but found that
participants reduced a mean of 40% of their baseline CPD over 12 weeks (Hecht et al.,
2004). One trial instructed participants to reduce 84-92% of their baseline CPD. This trial
did not report compliance or treatment length but found a mean reduction of 75% of
participants’ baseline CPD (Stein et al., 2002). Thus, it appears that large reductions in
CPD are possible but most participants do not comply with the instructed magnitude
(e.g., ≥50%) of reduction in CPD.
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Table 2: Studies that reported on the association between reduction in cigarettes per day (CPD) and dependence.
Author,
Year

N

Baseline
CPD

Methods

Cigarettes per day

Dependence

Participants randomized to either 6
Reduced 33% in the NRT
NRT-aided reduction resulted in
months of NRT-aided reduction in
group, 25% in the placebo
923
30
significantly lower FTCD scores than
CPD, placebo control, or no Tx
control, and 8% in the no Tx
the no Tx control.
control.
control.
Participants from a previous study
Reduced 86% with the
a
opted to reduce for 8 weeks with
Reduction aided by the standard NRT
Eclipse, 68% with the
Fagerstrom,
38
18-21
the aid of an Eclipse nicotine
inhaler significantly decreased FTCD
standard inhaler, and no
2002
inhaler, a standard NRT inhaler, or
with and without the CPD item.
change with no Tx.
no Tx.
Participants randomized to receive
Reduced 19% with reduction
4 weeks of brief telephone
Reduction in CPD was significantly
counseling, 11% with
Klemperer,
560
20
counseling to reduce CPD,
correlated with reduction in NDSS
motivational counseling, and
2015
increase motivation, or brief advice
scores among all participants.
9% with brief advice to quit.
to quit. No NRT was provided.
28
Participants were asked to recall
Reduction in CPD was significantly
Reduced 54% from peak
Mooney,
3,077
(lifetime their peak CPD and peak FTCD in
correlated with reduction in FTCD
CPD.
2014
peak)
their lifetime.
scores without the CPD item.
a
Reduction in FTCD scores were from the beginning of a prior 4-week cross over trial of NRT inhalers (Fagerstrom, Hughes, Rasmussen, & Callas,
2000) to the end of the 8 week reduction trial (Fagerstrom et al., 2002); CPD=Cigarettes per day; FTCD=Fagerstrom test for cigarette dependence
(unless stated otherwise, this measure includes CPD and thus is more sensitive to reduction interventions; (Fagerstrom, 2012)); N= Number of
participants in the trial; NDSS=Nicotine dependence syndrome scale (Shiffman et al., 2004); NRT=Nicotine replacement therapy; Tx=Treatment.
Etter,
2002
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Four studies examined the association between reducing CPD and changes in
dependence. One RCT of heavy smokers found that a nicotine replacement therapy
(NRT) aided intervention to reduce CPD resulted in significantly lower mean FTCD
scores (4.3) at a 6-month follow-up than the no treatment comparison condition (5.2)
(Etter et al., 2002). However, the FTCD scale included CPD and thus the reduction in
“dependence” could be solely due to a reduction in CPD. Another study included 38
participants who had participated in a previous 4-week cross over trial of NRT inhalers
(Fagerstrom et al., 2000) and opted to reduce CPD as much as possible with either the
standard or Eclipse over 2 months (Fagerstrom et al., 2002). Those who reduced CPD
with the standard inhaler had a significant reduction in FTCD scores from 5.6 at the
beginning of the initial cross over trial to 3.5 at the end of the reduction study
(Fagerstrom et al., 2002). Reduction in FTCD scores among those who used the Eclipse
(4.9 to 4.2) was not significant. Reductions in FTCD scores without the CPD item
remained significant for the standard inhaler and non-significant for the Eclipse
(Fagerstrom et al., 2002). A secondary analysis of 3,077 participants’ retrospective
reports of their current vs lifetime peak CPD found that reduction in CPD was highly
associated with a reduction in FTCD scores that were modified to exclude CPD (F=30.3)
(Mooney et al., 2011). Further, my unpublished secondary analysis of 560 smokers who
were not ready to quit and received brief telephone interventions without NRT found a
significant correlation between reduction in CPD and NDSS (dependence measure that
does not include CPD) scores over 2 months (r=0.31) and 6 months (r=0.35) (Klemperer
et al., 2015). In summary, reductions in CPD appear to be associated with decreased
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dependence (Etter et al., 2002; Fagerstrom et al., 2002; Klemperer et al., 2015; Mooney
et al., 2011).
In terms of biomarkers, medication-aided reduction in CPD decreases carbon
monoxide (CO) and cotinine more than placebo and no-treatment controls (Hughes &
Carpenter, 2005). However, analyses of changes in CO suggested some compensatory
smoking; specifically, CO decreased approximately 1/3 less than CPD among NRT-aided
reduction trials (Hughes, 2000; Hughes & Carpenter, 2005).
In terms of quitting, two reviews found that using medication to aid reduction in
CPD more than doubled the odds of point-prevalence and prolonged abstinence in
comparison to no treatment and placebo controls (Asfar et al., 2011; Moore et al., 2009).
One trial found NRT-aided reduction increased the odds of making a quit attempt over a
4.2 fold in comparison to no treatment (Carpenter, Hughes, Solomon, & Callas, 2004)
while another found that greater reduction in CPD without NRT also increased the odds
of making a QA (OR=1.19 (Klemperer, Hughes, Callas, & Solomon, 2017)). Both trials
found that reduction in CPD increased self-efficacy and intention to quit (Carpenter et al.,
2004; Klemperer et al., 2017).
In summary, most participants do not achieve interventions’ goals for large
reductions in CPD. Nevertheless, reducing some CPD (e.g., 19-68%) appears to have a
positive effect on dependence (Table 2). Though the reviewed studies’ methodologies
differ substantially, four of four relevant studies found significant associations between
reduction in CPD and reduction in dependence, including three trials that had dependence
measures not influenced by CPD. Thus it appears that CPD reduction interventions are
16

associated with decreased dependence even though most participants do not reduce to the
magnitude that they are instructed (i.e., they are not fully compliant).
1.2. Aims
Both switching to VLNC cigarettes and reducing CPD appears to decrease
dependence. Thus, in this trial I compared smokers who switch to VLNC cigarettes vs
reduce the number of full nicotine CPD. It appears that NRT is necessary to achieve
substantial reductions in CPD (Hughes, 2000; Hughes & Carpenter, 2005) (Hughes,
2000; Hughes & Carpenter, 2005). NRT also appears to increase the acceptability and
effectiveness of switching to VLNC cigarettes (Donny & Jones, 2009; Hatsukami et al.,
2013; Rose, Behm, Westman, & Kukovich, 2006; Walker et al., 2012). In both scenarios,
NRT could facilitate a net reduction in nicotine (Hurt et al., 1993). Thus I provided all
participants with 21-mg NRT patches.
Primary aims
1. Determine whether switching to VLNC cigarettes or reducing CPD is more acceptable
for smokers who are not ready to quit.
2. Determine whether switching to VLNC cigarettes or reducing CPD more effectively
reduces nicotine dependence.
Secondary aims
Determine whether switching to VLNC cigarettes vs reducing CPD:
3. Reduces cotinine (a nicotine metabolite) levels more.
4. Reduces carbon monoxide (CO) more.
5. Increases self-efficacy and intention to quit smoking more.
17

6. Increases quit attempts and 7-day point-prevalence abstinence more.
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CHAPTER 2: METHODOLOGY
2.1. Design
I conducted a two-arm, randomized trial using a sample of daily smokers not
ready to quit (n = 68) between February, 2017 and January, 2018 in Burlington, Vermont.
The study was approved by the Committee on the Use of Human Subjects in Research at
the University of Vermont and posted on www.clinicaltrials.gov (NCT03060083).
At participants’ initial visit, I randomly assigned participants to 1) switch to
VLNC cigarettes or 2) reduce full nicotine CPD (Table 3). During week 0, I provided all
participants with enough full nicotine study cigarettes to smoke as much as desired.
During weeks 1 through 4, I provided participants with 1) study cigarettes with
progressively less nicotine (i.e., switched to VLNC cigarettes) or 2) progressively fewer
number of full nicotine study cigarettes (i.e., reduced CPD). See section 2.3 for a full
description of nicotine dosage and reduction. I instructed participants to reduce a large
amount of nicotine (97%) over a relatively short period of time (4 weeks) because similar
reductions appear feasible and decreased dependence with VLNC cigarettes (Benowitz et
al., 2009; Benowitz et al., 2007) but has not been tested via reductions in CPD. I
instructed participants to do their best to smoke only study cigarettes throughout the
study period but to report the use of any non-study (i.e., usual brand) cigarettes on nightly
surveys. I informed participants that their compensation was not contingent on smoking
study cigarettes. Further, I used a bogus pipeline technique (Aguinis, Pierce, & Quigley,
1993) to increase participants’ self-report of non-study cigarettes that they smoked.
Specifically, I (falsely) informed participants that breath and urine tests could detect any
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non-study cigarettes that were smoked. I also provided participants with 21-mg NRT
patches and instructed them to use one patch per day throughout the study period to help
them switch to VLNC cigarettes or reduce CPD. I chose NRT patch primarily because it
can provide a consistent amount of nicotine to all participants. Further, NRT appears to
be safe, feasible, and effective when used to reduce CPD (Wu et al., 2015) or switch to
VLNC cigarettes (Hatsukami et al., 2013).
Participants who were randomized to reduce full nicotine CPD could not be
blinded. Thus, I informed participants who were randomized to switch to VLNC
cigarettes of the absolute nicotine content of their cigarettes each week as well as the
percent relative to the full nicotine cigarettes smoked at week 0.
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Table 3: Schedule of reduction and study visits.
Study Visit:

b

a

Switched to
VLNC
cigarettes

Reduced
number of full
nicotine CPD

b

0

Initial

b

1

b

2

c

3
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Week 0

Week 1

Week 2

Week 3

Cigarettes/day

Ad lib

100% of Week 0

100% of Week 0

100% of Week 0

Nicotine content

100%
(16.5 mg)

70%
(11.3 mg)

35%
(5.5 mg)

15%
(2.5 mg)

Cigarettes/day

Ad lib

70% of Week 0

35% of Week 0

15% of Week 0

Nicotine content

100%
(16.5 mg)

100%
(16.5 mg)

100%
(16.5 mg)

100%
(16.5 mg)

4

Week 4

100% of Week 0
3%
(0.4 mg)
d

3% of Week 0
100%
(16.5 mg)

Baseline cigarettes/day established during this time; bLaboratory visits when participants received 21-mg NRT patches and instructions to use one patch
per day; cLaboratory visit when participants were advised to quit; dParticipants received a minimum of 1 cigarette/day; CPD=Cigarettes per day;
mg/g=Milligram nicotine per gram tobacco; NRT=21-mg nicotine replacement therapy patch; VLNC=Very low nicotine content. Participants completed
an online follow-up survey 1 month after the end of week 4.
a

2.2. Participants
2.2.1. Recruitment
I contacted 359 potential participants with Internet advertising on Facebook and
Craigslist, flyers posted in the Burlington area, by word of mouth, and from lists of
individuals who completed or screened ineligible for other Tobacco Centers of
Regulatory Science (TCORS) studies at the University of Vermont and consented to have
their contact information shared (see Figure 3). Consenting participants could earn up to
$300 compensation for study participation. Compensation was not contingent on
compliance with the study reduction strategy or smoking study cigarettes. Seventy-four
consenting participants attended the initial study visit (see Table 3) and were randomized.
Importantly, differences between conditions did not begin until cigarettes were
distributed at the end of study visit 0. Thus, I excluded 6 participants who dropped out
after attending the initial study visit, before study visit 0 when nicotine reduction began
(Figure 3).
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Figure 3: Participant flow diagram.
CPD=Condition that reduced cigarettes/day; DSM-5=Diagnostic and Statistical Manual of Mental Disorders Fifth Edition; NRT=Nicotine
replacement therapy; TCORS=Tobacco Center on Regulatory Science; VLNC=Condition that switched to very low nicotine content cigarettes.

2.2.2. Sample Size
In my power analysis I calculated a necessary sample size of 32 per group for a
total of 64 participants to obtain a power of 0.8 with a two-sided alpha of 0.05 to detect a
10% within-group difference (0.5 units) in dependence using the Nicotine Dependence
Syndrome Scale (NDSS) given a standard deviation of 1. The NDSS is designed to
produce z-scores within a standard deviation of approximately 1 (Shiffman et al., 2004). I
selected the NDSS as the primary outcome measure because it is widely used, does not
rely on cigarettes/day, and has a 5-factor scale with good internal validity, test-retest
reliability, convergent validity, and predictive validity (Piper, McCarthy, & Baker, 2006;
Shiffman et al., 2004).
2.2.3. Inclusion Criteria
Inclusion criteria were a) ≥ 18 years old, b) smoke ≥10 cigarettes/day seven days
per week c) meet DSM-5 criteria for Tobacco Use Disorder, d) have no plans to stop
smoking in the next 30 days and is interested in reducing harm from smoking, e) is
willing to use NRT and has no contraindications to NRT use, f) have not used nontobacco nicotine products (e.g., electronic cigarettes) or non-cigarette tobacco products
(e.g., smokeless) in the last month, g) has not used nicotine replacement medications,
varenicline, bupropion, or received smoking cessation counseling in the last month, h)
has not reduced cigarettes/day by ≥ 25% in the last month, i) is currently or has
previously been a menthol smoker, j) is not prescribed or currently taking methadone or
buprenorphine, k) lives within a 1.5 hour drive of the University of Vermont, l) has been
smoking cigarettes daily for ≥ 1 year, m) has access to a telephone on a daily basis, o)
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typically goes to sleep between 8:00 PM and 2:00 AM (to maintain a consistent schedule
for nightly phone calls) p) is a US citizen or a permanent resident alien with a green card,
q) is comfortable reading and writing in English and demonstrates comfort speaking in
English, r) is not currently participating in another study that affects the way they smoke
cigarettes, and s) is not currently breastfeeding or planning to breastfeed in the next 3
months. Women were excluded if they were pregnant, planning to become pregnant in
the next 3 months, or of reproductive potential, sexually active, and not using protection
or on birth control. All women of reproductive potential also completed a pregnancy test,
whether they reported that they were sexually active or not, to verify that they were not
pregnant. I included smokers who tried to reduce cigarettes/day in the past but not in the
last month.
I recruited smokers with current or past experience smoking menthol cigarettes
because the only available VLNC study cigarettes that have consistent qualities (e.g.,
filter type and tipping paper perforation) across nicotine contents that allow for a gradual
transition to VLNC cigarettes are all mentholated. Therefore I provided all participants
with mentholated study cigarettes. A minority of smokers exclusively use menthol
cigarettes and most are African Americans (Samet et al., 2011); thus I anticipated a
limited number of menthol smokers in the Burlington area and therefore I did not believe
recruiting only menthol smokers was feasible. Instead, I recruited participants who have
experience smoking menthol cigarettes but usually smoke either menthol or non-menthol
cigarettes. I block randomized so that the proportion of usual menthol to non-menthol
cigarette smokers was similar between groups. Further, I compared usual menthol vs nonmenthol participants’ evaluations of study cigarettes at baseline using the modified
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cigarette evaluation questionnaire (Cappelleri et al., 2007) and tested menthol status as a
moderator of all outcomes (see section 2.5). Importantly, all participants in this study had
to adjust to the novel study cigarettes, regardless of their prior experience with menthol
cigarettes.
2.3. Procedure
I screened interested individuals via a 10-minute phone call or online survey to
determine eligibility. The initial study visit lasted approximately 1 hour. During this time,
I provided potential participants with a consent form and information regarding the study.
They were encouraged to ask questions and required to answer a short test to ensure they
understood study procedures prior to consenting to participate. Consenting participants
were then randomized to 1) the VLNC or 2) the CPD group. Peter Callas, a project
statistician, generated a concealed allocation sequence to randomize participant IDs to
experimental conditions. Blocked randomization was stratified by whether or not the
participant identified as a menthol smoker. All participants answered a series of
demographic questions and self-report measures regarding their smoking behavior, and
provided a breath sample for CO and urine sample for cotinine analysis. Female
participants of reproductive potential also completed a pregnancy test to verify that they
were not pregnant.
During week 0, I provided participants in both conditions with 16.5 mg/g nicotine
content study cigarettes totaling 150% of their self-reported number of cigarettes/day
from the week prior to entering the study. Participants were instructed to smoke ad-lib to
establish a baseline cigarettes/day with novel study cigarettes that were provided free of
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charge. The 16.5 mg/g nicotine content NIDA study cigarette is estimated to have a
nicotine yield (0.8 mg) similar to many commercial cigarettes. Participants were
instructed to smoke only study cigarettes, but to smoke as usual during week 0 of the
study. Self-reported cigarettes/day from week 0 served as the baseline cigarettes/day from
which I calculated the number of study cigarettes to provide participants during weeks 1
through 4 (see Table 3). Although participants were randomized and informed which
group they were in during their initial visit, all participants received identical instructions
for week 0.
2.3.1. Switching to VLNC Cigarettes
I provided participants who were randomized to switch to VLNC cigarettes with
100% of their number of week 0 cigarettes/day throughout weeks 1 to 4. They received
study cigarettes with progressively lower nicotine content (mg/g tobacco) beginning with
11.3 mg/g during week 1; 5.5 mg/g during week 2; 2.5 mg/g during week 3; and 0.4 mg/g
during week 4. I selected this schedule based on available VLNC cigarettes and findings
that suggest that gradual transitions to cigarettes with a nicotine content of ≤1 mg/g
decreases dependence (Benowitz et al., 2012; Benowitz et al., 2007; Hammond &
O'Connor, 2014). I also provided participants in this condition with a supply 21-mg NRT
patches with instructions to use one patch per day throughout weeks 1 through 4 to help
them switch to VLNC cigarettes. I estimated NRT use and compliance with VLNC study
cigarettes with daily and weekly self-report.
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2.3.2. Reducing CPD
I provided participants randomized to reduce CPD with full nicotine study
cigarettes (16.5 mg/g) throughout the 5-week study period and instructed them to only
smoke cigarettes provided by the study. After establishing a baseline cigarettes/day
during week 0, participants received progressively fewer cigarettes beginning with 70%
of their week 0 cigarettes/day for week 1; 35% for week 2; 15% for week 3; and 3% for
week 4. Participants received a minimum of 1 cigarette/day during week 4. I also
provided participants with a supply of 21-mg NRT patches with instructions to use one
patch per day throughout weeks 1 through 4 to help them reduce CPD. This schedule was
selected to match the VLNC condition’s percent reduction in nicotine and to encourage
participants to reduce as much as possible. I estimated reductions in CPD, compliance
with study cigarettes, and NRT use with daily and weekly self-report.
2.3.3. Schedule of Study Visits and Follow-up
All participants completed an initial visit as well as study visits once per week at
the end of weeks 0 through 4 (see the first row of Table 3). The initial visit occurred at
the beginning of week 0 and consisted of the consent process, randomization, study
instructions, an initial questionnaire, distribution of a 1-week supply of full nicotine study
cigarettes, and CO and urine samples. Subsequent weekly visits occurred at the end of
each week (i.e., visit 0 at the end of week 0, visit 1 at the end of week 1, etc) and
consisted of distribution of a weekly supply of study cigarettes and NRT patches as well
as completing self-report measures, CO samples, and urine samples (Table 3). See Table
4 for a description of when participants completed each measure throughout the study.
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Table 4: Schedule of outcome measures.
Assessed Throughout the 5-Week
Study Period
Nightly
Weekly
Acceptability Measures
Percent Non-Study
Cigarettes/Day

X

X
X

Acceptability Questionnaire
Dependence Measures
Nicotine Dependence Syndrome
Scales (NDSS)
Fagerstrom Test for Cigarette
Dependence (FTCD)
Glover-Nilsson Smoking
Behavioral Questionnaire
(GN-SBQ)
Addiction Ladder item
Time to First Cigarette item
(TTFC)
Biomarkers

Assessed 1 Month After the
Study Period
Follow-Up

X

X

X

X

X

X

X

X

X

X

X

Cotinine

X

Carbon monoxide (CO)

X

Quit Attempts and Cessation Measures
Self-Efficacy to Quit (SEQ)

X

X

Intention-to-Quit Ladder item

X

X

X

X

X

X

Plans to Quit Tomorrow item

X

Quit Attempts (QA)

X

7-Day Point-Prevalence
Abstinence (PPA)
30-Day Prolonged
Abstinence (PA)
IVR=Interactive voice response system.

X
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All participants’ completed a short online survey or called a toll free study
telephone number nightly throughout the 5 week study period using an Interactive Voice
Response (IVR) system. When accompanied by reimbursement that includes bonuses,
compliance to daily reporting is very high (e.g., 95%; (Hughes et al., 2014)). I asked
participants who quit during the study to continue to complete nightly questionnaires and
attend weekly study visits for the duration of the study.
At the final study visit, I provided all participants with a National Institutes of
Health (NIH) brochure regarding the dangers of smoking, information regarding
treatment options, and brief advice to quit. I offered an additional 1-month supply of
NRT patches to all participants regardless of whether they intended to quit. I did not
provide participants with study cigarettes after the 5-week study period. Participants
completed a final online survey 1 month after the end of the study period.
2.4. Measures
2.4.1. Acceptability
I calculated participants’ percent non-study (i.e., usual brand) cigarettes/day as
my primary measure of the degree to which switching to VLNC cigarettes or reducing the
number of CPD was an acceptable nicotine reduction strategy. Compliance with nicotine
reduction strategies has been used as a measure of acceptability in prior trials
(Mercincavage et al., 2017; Nardone et al., 2016). In the present study, participants
reported their number of study and non-study cigarettes/day on nightly questionnaires as
well as via timeline follow-back at weekly study visits. I treated missing days among
30

participants who also missed the prior week’s study visit (and thus did not receive studycigarettes for the week) as smoking 100% non-study cigarettes/day until they attended
their next study visit and received more study cigarettes. I encouraged participants to
accurately report non-study cigarettes by 1) falsely telling them I would detect non-study
cigarettes and 2) by explaining that smoking non-study cigarettes would not affect their
compensation or participation. Specifically, I read the following script to participants
prior to distribution of study cigarettes at the end of each study visit:
It’s important that you only smoke study cigarettes during this week. Our breath
and urine tests will detect any non-study cigarettes that are smoked. However, if
you slip and smoke non-study cigarettes it’s important that you report this as soon
as possible on your nightly surveys and weekly questionnaire. You will still be
able to participate in the study and will be paid for study activities. Your
reimbursement will not depend on how successful you are in using only our
cigarettes, however, you should do your best to achieve the goal this week.
I debriefed participants about the use of deception and its rationale at the final
study visit or via a mailed letter for those who missed the last study visit. Though prior
studies have proposed algorithms to calculate compliance using cotinine (Benowitz et al.,
2015; Foulds et al., 2018), these methods are not valid at smaller reductions in nicotine or
when using NRT (Benowitz, 2015). Thus, I relied on self-reported non-study
cigarettes/day as a measure of acceptability. Finally, I also tested the number of missed
study visits as a measure of acceptability because one reason for dropout or missing study
visits could be that the reduction strategy was not acceptable to the participant.
I created an acceptability questionnaire comprised of four single-item measures.
Specifically I asked all participants to consider the type and number of cigarettes they
were provided over the past week and report 1) how willing they are to smoke that type
31

of cigarette for the next year, 2) how able they are to smoke that type of cigarette for the
next year, 3) how willing they are to smoke that number of cigarettes for the next year,
and 4) how able they are to smoke that number of cigarettes for the next year. I used
mean Likert scale responses (1=least, 5=most) to each item for analysis.
2.4.2. Dependence
My primary measure of dependence is the Nicotine Dependence Syndrome Scale,
Overall Score (NDSS-OS; (Shiffman et al., 2004)). Secondary measures of dependence
included the five NDSS subscales: 1) the Drive subscale (NDSS-D) assessed craving,
withdrawal, and compulsion to smoke, 2) the Priority subscale (NDSS-P) assessed
preference for smoking over other reinforcers, 3) the Tolerance subscale (NDSS-T)
assessed sensitivity to the effects of smoking, 4) the Continuity subscale (NDSS-C)
assessed the regularity of smoking rate, and 5) the Stereotypy subscale (NDSS-S)
assessed changes in invariance of smoking. The NDSS scales have good reliability and
predictive validity (Piper et al., 2006) and are not influenced by changes in cigarettes/day.
The NDSS produces z-scores and the scores are calculated with weighted parameters
using subsets of the 19 NDSS items (Shiffman et al., 2004).
I also used a version of the Fagerstrom Test for Cigarette Dependence (FTCD;
(Fagerstrom, 2012)) modified to exclude the cigarettes/day item. Responses on the FTCD
were summed (0=least and 7=most dependent) for analysis. I excluded cigarettes/day
from the FTCD because reducing cigarettes/day was inherent to the strategy used by the
CPD reduction condition. The FTCD is the most commonly used measure of dependence.
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However, findings are mixed regarding the FTCD’s predictive validity, internal validity,
and reliability (Piper et al., 2006).
The Glover-Nilsson Smoking Behavioral Questionnaire (GN-SBQ) is a measure
developed specifically to assess the role of behavior in cigarette dependence (Glover et
al., 2005). For example, the GN-SBQ includes: “Do you find yourself lighting a cigarette
routinely (without craving)?” and “Does part of your enjoyment of smoking come from
the steps (ritual) you take when lighting a cigarette?” Participants responded to items
using a 0 to 4 Likert scale and I summed responses for analysis (0=least dependent,
44=most dependent). I included the GN-SBQ to assess changes in dependence due to
changes in behavioral conditioning that could occur from switching to VLNC cigarettes
or reducing CPD (see section 1.1). Though the GN-SBQ has been used in prior reduction
studies (O'Brien, Knight-West, Walker, Parag, & Bullen, 2015; Tseng et al., 2016), I
could not find a test of the measure’s validity or reliability.
Importantly, the NDSS, FTCD, and GN-SBQ are traditionally used to assess
longer-term and stable states of dependence. I was unable to find a measure designed to
assess short-term changes in dependence. Thus, I modified instructions for these
measures to assess shorter-term changes in dependence within the 5-week study period as
well as on the follow-up questionniare. I instructed participants to respond to all
questions only considering their symptoms during the prior 7 days. In addition, I
modified the wording of some questions and included a “not applicable” response option.
For example, many participants responded “not applicable” to the FTCD question: “In
the past 7 days, did you smoke even when you were so ill that you were in bed most of
the day?” I recoded all “not applicable” responses as “no” for these dependence measures
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to minimize missing data. A participant who selected “not applicable” likely did so
because they did not come into contact with, and thus did not experience, the symptom
assessed by the question. Dependence measures at the initial visit asked about pre-study
symptoms and thus were not modified. Therefore, dependence measures collected at the
initial study visit are not comparable to dependence measures at study visits 0 through 4
or at follow-up.
In addition to the NDSS, FTCD, and GN-SBQ measures, I included two singleitem measures of dependence. First, I assessed time to first cigarette (TTFC) after
waking. TTFC is an item on the FTCD that correlates well with other measures of
dependence (Fu et al., 2011), has good predictive validity for QAs and cessation (Baker
et al., 2007; Borland, Yong, O'connor, Hyland, & Thompson, 2010) and is thought to be
one of the best single questions to assess dependence (Fagerstrom, 2003). Second, I used
an Addiction Ladder to assess changes in how addicted participants felt to cigarettes. This
item was adapted from the Intention-to-Quit Ladder (Hughes, Keely, Fagerstrom, &
Callas, 2005) and instructed participants to indicate on a Likert scale of 0 (not at all) to 10
(very definitely) how addicted to cigarettes they currently felt. The Addiction Ladder has
not been validated in prior studies.
2.4.3. Biomarkers
I collected weekly urine samples to measure changes in cotinine to assess the
effectiveness of switching to VLNC cigarettes vs reducing CPD at reducing nicotine
exposure. I analyzed urinary cotinine levels using semi-quantitative on-site enzyme
immunoassay (Microgenics, Fremont, CA, USA). Cotinine is a nicotine metabolite with a
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half-life of approximately 16 hours (Benowitz & Jacob, 1994; West & Hajek, 2011).
Smoking within the past 80 hours generally results in elevated urine cotinine levels and
thus cotinine is a commonly used measure of nicotine exposure (Benowitz et al., 2002).
Changes in cotinine could be influenced by differences in nicotine content, compensatory
smoking (e.g., inhaling more vigorously), or number of cigarettes as well as NRT use.
I collected weekly breath samples to measure changes in carbon monoxide (CO)
to assess the extent to which participants in each condition reduced their smoke exposure.
I analyzed breath samples using a handheld Covita Micro Smokelyzer
(http://www.covita.net/). CO is a byproduct of combusted tobacco and has a half-life of
approximately 4 hours. Smoking within the past 24 hours generally results in elevated
breath CO levels and thus CO is commonly used only as a short-term measure of
cigarette smoke exposure (Benowitz et al., 2002). Changes in CO could be influenced by
differences in recency, compensatory smoking, or number of cigarettes, but is not directly
affected by NRT or the nicotine content of cigarettes. Importantly, I instructed CPD but
not VLNC participants to reduce the number of cigarettes/day. Thus I expected CO to
change in the CPD condition but not necessarily in the VLNC condition.
2.4.4. Quit Attempts and Cessation Measures
The Self-Efficacy to Quit (SEQ) measure is a commonly used self-efficacy scale
in smoking research (Velicer, DiClemente, Rossi, & Prochaska, 1990). Increases in the
SEQ has predicted cessation and quit attempts in prior reduction studies (Carpenter et al.,
2004; Klemperer et al., 2017). Participants responded to SEQ questions on a 5-point
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Likert scale and I calculated the mean response for an overall score (1=least and 5=most
self-efficacy to quit).
The Intention-to-Quit Ladder is a single item that instructs smokers to indicate on
a 0 (very definitely no) to 10 (very definitely yes) Likert scale how much they intend to
quit in the next 30 days (Hughes et al., 2005). Increases in the Intention-to-Quit ladder
has predicted cessation and quit attempts in prior reduction studies (Carpenter et al.,
2004; Klemperer et al., 2017).
I measured plans to quit tomorrow using a single item on nightly surveys.
Specifically, I asked smokers whether they planned to smoke tomorrow rather than if
they planned to quit tomorrow because a prior study found that asking about intentions to
stop repeatedly (e.g., on 35 occasions) could make participants feel under pressure to try
to quit (Hughes et al., 2014). Thus, days when participants reported they did not intend to
smoke were considered days when participants planned to quit. In a prior prospective
natural history study, plans to quit tomorrow predicted future quit attempts and cessation
(Hughes et al., 2014).
I measured quit attempts (QA) that lasted ≥24 hours as well as any QAs (i.e.,
including very short QAs that lasted < 1 day) using nightly and weekly self-reports. A
prior prospective study found QAs (including very short attempts) predicted future longer
abstinence (Hughes et al., 2014). Further, making a QA is an inherent pre-requisite to
cessation. I did not biochemically verify QAs because many were short and occurred
between study visits.
I measured self-reported 7-day point-prevalence abstinence (PPA) weekly and at
the online follow-up 1 month after the study period. I measured 30-day prolonged
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abstinence (PA) at the 1-month follow-up. Both PPA and PA are commonly used and
clinically meaningful outcomes in smoking research (Hughes et al., 2003). I did not
biochemically verify abstinence during follow-up because I lacked sufficient funds to
collect breath or urine samples during the follow-up period.
2.4.5. Measures Collected But Not Reported in This Dissertation
The following outcomes were collected during this study and will be reported in
future publications but not in my dissertation: Questionnaire of Smoking Urges – brief
scale (Cox, Tiffany, & Christen, 2001), Minnesota Nicotine Withdrawal Scale (Hughes &
Hatsukami, 1986), Perceived Health Risks Rating (Westman, Levin, & Rose, 1992);
Cigarette Purchase Task (MacKillop et al., 2008); modified Cigarette Evaluation
Questionnaire (Cappelleri et al., 2007).
2.5. Analysis
I conducted all analyses with SPSS (IBM SPSS Statistics for Windows, Version
24.0. Armonk, NY: IBM Corp.) I used multi-level modeling for between-participant
comparisons (i.e., VLNC vs CPD groups), within-participant comparisons (i.e., week 0 to
week 4), and a condition by time interaction for all continuous and ordinal outcomes.
Though some of my outcomes were collected daily, I used week as my time variable for
all outcomes because parameter estimates are less accurate in multi-level models with
small sample sizes (e.g., N=68) and large number of time-points (e.g., 35 days; (Bijleveld
et al., 1998)). Thus, I aggregated nightly data to weekly means in order to have fewer
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time-points for this relatively small sample. For binary outcomes, I used logistic
regression and Cox regression survival analyses.
2.5.1. Analysis of Continuous and Ordinal Outcomes
The following were continuous or ordinal outcomes: Percent non-study CPD,
Acceptability Questionnaire items, NDSS overall scale and subscales, FTCD, GN-SBQ,
TTFC, Addiction Ladder, Cotinine, CO, SEQ, and Intention-to-Quit Ladder. In order to
test for stability at week 0, I used multi-level modeling to conduct between-participant,
within-participant, and day by condition interactions as predictors of changes in measures
assessed nightly during week 0: Percent non-study CPD, addiction ladder, TTFC, and
total (study + non-study) CPD. None were significant, indicating that participants
established stable smoking when they received free study cigarettes to smoke ad-lib
during week 0 of the study period.
In my main multi-level models, I entered time and condition as fixed effects and
participants as a random effect. I compared Akaike and Bayesian information criteria
(AIC and BIC) values between the following covariance structures to choose the best
fitting model for each outcome: First order auto-regressive, first order auto-regressive
heterogeneous, variance covariance, compound symmetry, and unstructured.
In my between-participant comparisons, I entered condition (VLNC vs CPD) as
the predictor and collapsed across weeks 1 through 4. I excluded week 0 in my primary
between-participant analyses because reduction did not begin until week 1. Next I
collapsed across condition and entered time (i.e., weeks 0 to 4) as the predictor. I also
tested time as a predictor of all outcomes separately among VLNC and CPD participants.
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Finally, I entered condition, time, and a condition by time interaction as predictors in my
full multi-level model.
I tested my full multi-level interaction model (condition, time, and condition by
time interaction), when controlling separately for 1) NRT patch compliance and 2)
percent non-study cigarettes/day as time-varying covariates. I controlled for NRT patch
compliance to examine whether the effectiveness of the nicotine reduction strategies was
due to NRT use. I defined NRT compliance as the percent of days during weeks 1
through 4 when participants reported using the patch. I controlled for percent non-study
cigarettes/day to examine the extent to which findings could be due to differences in the
reduction strategies’ acceptability. Thus, I did not control for percent non-study
cigarettes/day for acceptability outcomes. Importantly, I conceptualized percent nonstudy cigarettes/day as a potential mediator (not a confounder) of the reduction strategies’
influence on dependence, biomarkers, and quitting.
Finally, I tested gender and menthol status (i.e., whether the smoker identified as
a menthol or non-menthol smoker at screening) as moderators of all outcomes. However,
neither gender nor menthol status moderated any of my outcomes. Therefore I did not
report on findings from these analyses in my results.
In a series of post-hoc tests, I compared VLNC vs CPD participants 1) at the end
of the study period (week 4) on all continuous and ordinal outcomes and 2) at each week
among outcomes where there was a significant condition by time interaction. I also
examined within-participant changes in total (study + non-study) cigarettes/day to
provide context to interpret changes in percent non-study cigarettes/day (i.e.,
acceptability) throughout the study period.
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2.5.2. Analysis of Binary Outcomes
The following were binary outcomes: Plans to quit tomorrow, any QA, and ≥24
hour QA. I used logistic regression to compare VLNC vs CPD conditions. Using Cox
regression survival analyses, I calculated Cox Hazard Ratios and compared time to first
event. I also tested all Cox regression survival analyses when controlling separately for 1)
percent non-study CPD and 2) NRT patch compliance as time-varying covariates.
2.5.3. Analysis of Follow-Up Outcomes
I analyzed the following continuous or ordinal outcomes at the 1-month followup: Total cigarettes/day, NDSS-OS, FTCD, GN-SBQ, Addiction Ladder, SEQ, and
Intention-to-Quit Ladder. I used linear regression to compare VLNC vs CPD at followup, change from the end of the study period (week 4) to follow-up, change from prestudy to follow-up, and all condition by time interactions. Finally I tested all condition by
time interactions after controlling for patch distribution and use during follow-up.
Dichotomous outcomes were whether participants set a quit date at their final
study visit and self-reported 7-day PPA and 30-day PA at the 1-month follow-up. I used
chi-square tests to compare differences between VLNC vs CPD groups.
2.5.4. Missing Data
There were no significant differences in the number of missed study visits
between conditions. Of the 74 consented participants, six did not attend study visit 0 and
thus were excluded from my analyses. Of the 68 participants included in my analyses,
five participants missed all visits after visit 0, one participant missed visit 1 only, one
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participant missed visits 2 through 4, three participants missed visits 3 and 4, one
participant missed visit 3 only, and one participant missed visit 4 only. Three hundred
and twenty-six (14%) of the 2,380 total nightly IVR surveys (68 participants x 35 day
study period) were missing. Participants reported cigarettes/day, TTFC, Addiction
Ladder, and QAs on both nightly and weekly surveys (see Table 4). When possible, data
from nightly surveys were used for analysis to minimize recall bias. However, in order to
minimize missing data, values from weekly surveys were used to impute missing nightly
data when participants attended a weekly visit but missed nightly surveys during the
subsequent week. After imputing data from weekly surveys, 209 (9%) of the 2,380 total
nightly surveys remained missing. Twenty eight (41%) participants missed the online
follow-up survey 1 month after the study period. The amount of missing nightly, weekly,
and follow-up data did not significantly differ between conditions. Importantly, because I
used multi-level modeling for my main analyses of continuous and ordinal data, all
missing data were accounted for by the model (Field, 2013). Missing binary data (e.g.,
QA and cessation) were handled by censoring in my survival analyses and treated as
continued smoking in follow-up analyses. Missing continuous data at follow-up (e.g.,
dependence measures) were treated as missing. I examined the distributions of all
outcomes at all time points and none required transformation. I examined all outliers that
were beyond two standard deviations from the mean for each outcome at each time point
and found no reason to exclude any data.
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2.6. Participant Characteristics
Compared with population based samples of current daily smokers (Fagerstrom
& Furgerg, 2008; Hughes & Callas, 2010) smokers in this study appear younger, more
likely to be male, more likely to be white, non-Hispanic, more educated, more dependent,
and smoked more cigarettes/day before the study began (Table 5). There were no
significant differences between CPD and VLNC participants.
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Table 5: Participant demographics and smoking history.a
VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

NHISb and other
surveysc,d

Mean Age

38.4 (13.4)

39.3 (13.6)

38.8 (13.4)

42b

% Women

38.9

40.6

39.7

46b

% White, non-Hispanic

77.8

87.5

82.4

78b

% with > 12 years of education

72.2

71.9

72.1

39b

% Employed full time

47.2

37.5

42.6

-

% Married

30.6

25.0

27.9

-

19.0 (6.1)

19.8 (10.4)

19.4 (8.4)

16b

5.3 (1.9)

5.0 (2.2)

5.1 (2.0)

4.3-4.6c

2.4 (1.1)

2.3 (0.9)

2.4 (1.0)

-

3.4 (3.0)

3.5 (3.0)

3.5 (3.0)

-

22.4 (11.7)

22.3 (11.2)

22.3 (11.4)

-

Mean cotinine ng/ml

1,364.1 (739.4)

1,464.5 (703.2)

1,412.1 (718.7)

-

% Menthol smokers

22.2

25.0

23.5

38.8d

16.7 (4.7)

15.6 (3.3)

16.2 (4.1)

17b

Demographics

e
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Smoking history
Mean cigarettes/day

Mean total Fagerstrom Test for Cigarette
Dependence (0=lowest, 10=highest)
Mean self-efficacy to quit
(1=lowest, 5=highest)
Mean Intention to quit in the next month
(0=very definitely no, 10=very definitely yes)
Mean carbon monoxide (CO) ppm

Mean age at onset of smoking

VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

NHISb and other
surveysc,d

1.0 (1.5)

2.4 (6.3)

1.7 (4.5)

-

Median number of QAs in life

2.0

3.0

2.0

-

% Used NRT during a past QA

52.8

40.1

Number of times attempted to reduce but
not quit in past 12 months

a

b

c

47.1
d

e

Standard deviations in parentheses; (Hughes & Callas, 2010); (Fagerstrom & Furgerg, 2008); (Villanti et al., 2016); Assessed at the initial study
visit; CPD=Condition that reduced cigarettes per day; NHIS=United States National Health Interview Survey; QA=Quit attempts; VLNC=Condition
that switched to very low nicotine content cigarettes.
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CHAPTER 3: RESULTS
Due to the large number of outcomes in this study, magnitudes of effects are
displayed in tables and figures but not reported in the text for most outcomes. In addition,
see Appendix Table 1 for raw means for all outcomes at week 0, week 4, and follow-up.
3.1. Smoking at Week 0
During week 0, all participants received 150% of the number of their pre-study
cigarettes/day and were instructed to smoke study cigarettes with 16.5 mg/g nicotine adlib. Participants smoked about a pack per day and smoked very few non-study cigarettes
(see Table 6). Though prior research indicates that participants smoke more cigarettes
when they are free (Shiffman & Scholl, 2017), differences between pre-study commercial
cigarettes/day (mean= 19.4) and week 0 total cigarettes/day (mean=20.6) were not
significant. There were no differences between participants’ evaluation of study
cigarettes (mCEQ) based on condition or whether participants identified as a menthol
smoker prior to entering the study. Importantly, there were no differences between VLNC
and CPD groups during week 0 and smoking characteristics remained stable over time
throughout week 0 (see section 2.5).
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Table 6: Week 0 smoking characteristics.a
VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

20.1 (8.8)

21.1 (12.2)

20.6 (10.5)

1.5

1.0

1.2

4.3 (1.1)

4.4 (0.9)

4.4 (1.0)

4.1 (1.2)

4.1 (1.1)

4.1 (1.2)

4.3 (1.1)

4.2 (1.0)

4.2 (1.1)

4.1 (1.3)

3.8 (1.1)

3.9 (1.2)

-0.70 (.85)

-0.77 (0.92)

-0.73 (0.88)

3.1 (1.4)

3.0 (1.5)

3.0 (1.5)

15.7 (6.5)

16.1 (6.6)

15.9 (6.5)

8.6 (1.9)

8.9 (1.2)

8.7 (1.6)

24.8 (20.2)

24.0 (23.0)

24.4 (21.4)

2.4 (1.1)

2.9 (1.0)

2.7 (1.0)

4.5 (3.5)

4.0 (3.5)

4.3 (3.5)

1,327.1 (665.2)

1,266.7 (567.2)

1,298.3 (616.5)

24.9 (14.0)

22.5 (12.1)

23.8 (13.1)

Mean total cigarettes/day
Median percent non-study cigarettes/day
Mean willingness to smoke type of cigarette
(1=least, 5=most)
Mean ability to smoke type of cigarette
(1=least, 5=most)
Mean willingness to smoke number of cigarettes
(1=least, 5=most)
Mean ability to smoke number of cigarettes
(1=least, 5=most)
Mean Nicotine Dependence Syndrome Scale,
Overall Score (NDSS-OS; z-scores)
Mean Fagerstrom Test for Cigarette
Dependence (FTCD; excluding cigarettes/day;
0=lowest, 7=highest)
Mean Glover-Nilsson Behavioral Dependence
Questionnaire (GN-SBQ; 0=lowest, 44=highest)
Mean Addiction Ladder
(0=lowest, 10=highest)
Mean time to first cigarette (TTFC)
in minutes
Mean self-efficacy to quit
(SEQ; 1=lowest, 5=highest)
Mean Intention-to-Quit Ladder
(0=lowest, 10=highest)
Mean cotinine ng/ml
Mean carbon monoxide (CO) ppm
a

Standard deviations in parentheses; CPD=Condition that reduced cigarettes per day; ng/ml=Nanograms
per milliliter; ppm=Parts per million; VLNC=Condition that switched to very low nicotine content
cigarettes. Responses are from visit 0.
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3.2. Nicotine Replacement Therapy (NRT) Patch Compliance
I provided participants with NRT patches to use daily throughout weeks 1
through 4 to help them reduce. Participants reported NRT use on their nightly and weekly
surveys. In the VLNC condition, participants used NRT a median of 82% of days and
44% of participants used NRT > 90% of days. In the CPD condition, participants used
NRT a median of 95% of days and 56% of participants used NRT > 90% of days.
Differences between VLNC and CPD participants were not significant.
3.3. Acceptability Outcomes
I tested percent non-study cigarettes/day and participants’ willingness and
ability to smoke the number and type of study cigarettes to determine whether
acceptability differed between VLNC vs CPD or over time. When collapsed across time,
CPD participants smoked more non-study cigarettes/day and reported that they were less
willing and less able to continue smoking their reduced number of cigarettes/day in
comparison to VLNC participants (Table 7).
When collapsed across conditions, percent non-study cigarettes/day increased
from week 0 to the end of the study period (week 4). Participants’ willingness and ability
to continue smoking the number of study cigarettes provided decreased over time. I also
tested within-participant changes separately among VLNC and CPD participants.
Among VLNC participants, there were no significant changes over time for percent nonstudy cigarettes/day, willingness or ability to smoke number of cigarettes, or willingness
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or ability to smoke type of cigarettes. Among CPD participants there was an increase
over time in percent non-study cigarettes/day (F=42.2, p<.001) and decreases in
willingness (F=11.1, p<.001) and ability (F=9.8, p<.001) to smoke the number of
cigarettes provided. There was no significant change in willingness or ability to smoke
the type of cigarettes provided among CPD participants.
There were condition by time interactions where 1) CPD participants’ percent
non-study cigarettes/day increased over time while VLNC participants’ did not (Figure 4
and Figure 5), and CPD participants’ willingness (Figure 6) and ability (Figure 7) to
continue smoking their reduced number of cigarettes declined over time while VLNC
participants’ did not. These interactions remained significant after controlling for
participants’ NRT patch use throughout the study period.
I also examined changes in total (study + non-study) cigarettes/day over time to
provide context for changes in percent non-study cigarettes/day. Despite the apparent
unacceptability among the CPD reduction group, mean total (study + non-study)
cigarettes/day decreased by 60% for CPD participants (F=17.9 p<0.001). Also, despite no
instructions to reduce number of cigarettes, total cigarettes/day decreased by 19% for
VLNC participants (F=8.1 p<0.001; Figure 8).
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Table 7: Acceptability outcomes.a
VLNC vs CPD
(collapsed across weeks
1 to 4)

Week
(collapsed across
condition)

Condition x Week
(interaction)

Condition x Week
(controlling for NRT
patch use)

% Non-Study Cigarettes/Day

5.0*

26.3***

8.0***

29.5***

Willingness to smoke type
of cigarette

0.01

0.2

0.7

0.5

Ability to smoke type
of cigarette

0.5

1.0

0.8

0.4

10.4**

5.7***

4.0**

6.0***

Willingness to smoke number
of cigarettes

Ability to smoke number
16.0***
4.8**
3.5**
4.1***
of cigarettes
a
F values are reported; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced cigarettes per day; NRT=Nicotine replacement therapy;
VLNC=Condition that switched to very low nicotine content cigarettes.
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100%
90%

50

Percent Non-Study Cigarettes/Day

80%
70%
60%
50%

Mean CPD

40%
Mean VLNC
30%

20%
10%
0%

Figure 4: Condition by week interaction predicts percent non-study cigarettes/day: Weekly means from multi-level model.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.
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90%
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Percent Non-Study Cigarettes/Day

80%
70%
60%
50%

Mean CPD

40%
30%

Mean VLNC

20%
10%
0%

Week 0 (100% nic)

Week 1 (70% nic)

Week 2 (35% nic)

Week 3 (15% nic)

Week 4 (3% nic)

Figure 5: Condition by week interaction predicts percent non-study cigarettes/day: Daily raw data.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.
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1=Definitely No; 5=Definitely Yes

4.5

4.0

3.5

3.0

2.5

2.0
Mean CPD

Mean VLNC

1.5

1.0

Figure 6: Condition by week interaction predicts willingness to continue smoking the number of cigarettes/day.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.
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1=Definitely No; 5=Definitely Yes

4.5

4.0

3.5

3.0

2.5

2.0
Mean CPD

Mean VLNC

1.5

1.0

Figure 7: Condition by week interaction predicts ability to continue smoking the number of cigarettes/day.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.
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CPD condition: Mean total (study + non-study) cigarettes/day
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Figure 8: Changes in total (study + non-study) cigarettes/day.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.

3.3.1. Acceptability Outcomes Post-hoc Tests
The difference in missed study visits between VLNC (missed 3% of visits) vs
CPD (missed 4% of visits) participants was not significant. I compared VLNC vs CPD
participants 1) at the end of the study period (week 4) for all outcomes and 2) at each
week when there was a significant condition by time interaction. Percent non-study
cigarettes/day and willingness and ability to smoke the number of cigarettes were the
only outcomes that differed at week 4 (Table 8). CPD participants’ percent non-study
cigarettes/day became significantly greater than VLNC participants at week 3 and
continued for the duration of the study period. CPD participants’ reported willingness and
ability to smoke their reduced number of cigarettes became significantly less than VLNC
participants at week 2 and continued for the duration of the study period.
Table 8: VLNC vs CPD comparisons at each week: Acceptability.a
Week 0
(100% nic)

Week 1
(70% nic)

Week 2
(35% nic)

Week 3
(15% nic)

Week 4
(3% nic)

Percent non-study
0
1.7
2.9†
15.2***
23.0***
cigarettes/day
Willingness to
0.1
1.2
6.8*
10.9**
17.6**
smoke number of
cigarettes
Ability to
0.8
4.6†
11.6**
16.8***
16.8***
smoke number of
cigarettes
a
F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced
cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes;
Only outcomes that had a significant condition by time interaction were tested at each week.

3.3.2. Acceptability Summary
Overall, reduction was more acceptable in the VLNC than CPD group. There
was also a significant decline in acceptability for CPD but not VLNC participants as
they reduced over time. Reducing became less acceptable to CPD than VLNC
participants at week 2 (35% nicotine) for willingness and ability to smoke the number
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of study cigarettes and week 3 (15% nicotine) for percent non-study cigarettes/day.
Acceptability of switching to VLNC cigarettes did not decline over time. Thus, even
with the aid of NRT, reducing CPD became progressively less acceptable while
switching to VLNC cigarettes remained an acceptable strategy to reduce nicotine.
3.4. Dependence Outcomes
I tested dependence measures to determine which reduction strategy was more
effective and whether the strategies became more effective over time with greater
reductions. When collapsed across time, there were no significant differences between
VLNC vs CPD participants on any measure of dependence (Table 9).
When collapsed across conditions, dependence decreased from week 0 to the
end of the study period on the NDSS Overall Scale, NDSS Drive subscale, FTCD without
cigarettes/day, GN-SBQ, TTFC, and Addiction Ladder. I also tested within-participant
changes separately among VLNC and CPD participants. Among VLNC participants,
there were significant decreases in NDSS Overall Score (F=10.5, p<.001), NDSS Drive
subscale (F=16.3, p<.001), FTCD scores without cigarettes/day (F=3.7, p<.05), GN-SBQ
(F=6.1, p<.01), TTFC (F=4.8, p<.001), and Addiction Ladder scores (F=7.2, p<.001)
over time but not the NDSS Stereotypy, Priority, Tolerance, or Continuity subscales.
Among CPD participants there were significant decreases in NDSS Overall Score (F=5.0,
p<.01), NDSS Drive subscale (F=3.4, p<.05), GN-SBQ (F=6.0, p<.01), TTFC (F=3.9,
p<.01), and Addiction Ladder scores (F=10.2, p<.001) over time but not FTCD scores
without cigarettes/day or the NDSS Stereotypy, Priority, Tolerance, or Continuity
subscales.
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There were condition by time interactions where VLNC participants’
dependence decreased more over time than CPD participants on the NDSS Overall Score
(Figure 9), NDSS Drive subscale (Figure 10), and the Addiction Ladder (Figure 11). The
NDSS Overall Score remained significant after controlling for NRT patch use but was no
longer significant when controlling for percent non-study cigarettes/day. The NDSS
Drive subscale remained significant after controlling for both covariates. The Addiction
Ladder was not significant after controlling for either covariate.
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Table 9: Dependence outcomes.a

NDSS Overall Score
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NDSS Stereotypy
Subscale
NDSS Priority
Subscale
NDSS Tolerance
Subscale
NDSS Continuity
Subscale
NDSS Drive
Subscale
FTCD without
cigarettes/day
GN-SBQ
TTFC
Addiction Ladder

VLNC vs CPD
(collapsed across
weeks 1 to 4)

Week
(collapsed across
condition)

Condition x Week
(interaction)

Condition x Week
(controlling for NRT
patch use)

Condition x Week
(controlling for
percent non-study
cigarette/day)

0

13.9***

3.2*

3.0*

1.0

1.0

1.4

0.8

0.9

0.2

0.6

0.6

0.6

0.3

0.7

1.4

0.9

0.1

0.3

0.7

3.4†

0.8

0.7

0.5

1.2

0.5

14.7***

3.3*

3.5*

5.1**

0.1

4.4**

0.5

0.4

1.2

0

12.8***

0.1

0.2

1.2

0.2

7.6***

1.1

0.4

1.9

0

24.1***

2.4*

1.8

0.5

F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced cigarettes per day; FTCD=Fagerstrom test for
cigarette dependence; GN-SBQ=Glover-Nilsson Smoking Behavior Questionnaire; NDSS=Nicotine dependence syndrome scale; NRT=Nicotine
replacement therapy; TTFC=Time to first cigarette; VLNC=Condition that switched to very low nicotine content cigarettes.
.
a

0.0
Week 0 (100% nic)

Week 1 (70% nic)

Week 2 (35% nic)

Week 3 (15% nic)

Week 4 (3% nic)

-0.2
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More negative numbers = less dependence
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-1.6
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Mean CPD

Mean VLNC

Figure 9: Condition by week interaction predicts NDSS Overall Score.
CPD=Condition that reduced cigarettes per day; NDSS=Nicotine Dependence Syndrome Scale; nic=Nicotine; VLNC=Condition that switched to very
low nicotine content cigarettes.
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Figure 10: Condition by week interaction predicts NDSS Drive subscale score.
CPD=Condition that reduced cigarettes per day; NDSS=Nicotine Dependence Syndrome Scale; nic=Nicotine; VLNC=Condition that switched to very
low nicotine content cigarettes.
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Figure 11: Condition by week interaction predicts Addiction Ladder.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.

3.4.1. Dependence Outcomes Post-hoc Tests
The NDSS Drive subscale was the only measure where participants differed
significantly at week 4: VLNC participants had significantly less dependence than CPD
participants. Differences between VLNC and CPD participants were not significant at
any single week in my post-hoc comparisons of dependence on the NDSS Overall Scale
and Addiction Ladder (Table 10).
Table 10: VLNC vs CPD comparisons at each week: Dependence.a
Week 0
Week 1
Week 2
Week 3
(100% nic)
(70% nic)
(35% nic)
(15% nic)
NDSS Overall
Score
NDSS Drive

Week 4
(3% nic)

0

0

0

0

2.9†

0.5

0

0.1

1.2

7.3*

Addiction
0.5
0.2
0.3
0
2.3
Ladder
a
F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced
cigarettes per day; NDSS=Nicotine dependence syndrome scale; nic=Nicotine; VLNC=Condition that
switched to very low nicotine content cigarettes. Only outcomes that had a significant condition by time
interaction were tested at each week.

3.4.2. Dependence Summary
There were no overall differences in dependence between switching to VLNC
cigarettes vs reducing CPD. However, dependence significantly declined over time for
both groups on most measures. On my primary and two secondary measures of
dependence, there were interactions in which dependence decreased more over time for
VLNC than CPD participants. This effect appeared largest on the NDSS Drive subscale
which measured craving, withdrawal, and compulsion to smoke. Thus, with the aid of
NRT, both VLNC and CPD conditions decreased dependence. However, switching to
VLNC cigarettes appears more effective at decreasing dependence at greater magnitudes
of reduction.
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3.5. Biomarker Outcomes
I tested cotinine to determine which reduction strategy was more effective at
decreasing nicotine exposure and whether nicotine exposure decreased more over time.
Nicotine was supplemented via NRT patch during weeks 1 through 4 but this did not
differ by week or condition. I tested CO to determine which reduction strategy decreased
smoke exposure more and whether this changed over time. Importantly, CPD participants
were, but VLNC participants were not instructed to reduce smoking. When collapsed
across time, cotinine values were significantly less for VLNC than CPD participants
(Table 11). In contrast, CO values were significantly less for CPD than VLNC
participants.
When collapsed across conditions, both cotinine and CO decreased over time. I
also tested within-participant changes separately among VLNC and CPD participants.
Among VLNC participants, both cotinine (F=9.9, p<.001) and CO (F=2.7, p<.05)
declined over time. Among CPD participants, cotinine increased, not decreased, over
time (F=2.5, p<.05) and CO decreased over time (F=5.8, p<.001).
There were condition by time interactions where 1) cotinine decreased for
VLNC participants but increased for CPD participants over time (Figure 12) and 2) CPD
participants’ CO values decreased more at weeks 1 to 3 than VLNC participants (Figure
13). The condition by time interactions for both cotinine and CO remained significant
after controlling for NRT patch use but were no longer significant when controlling for
percent non-study cigarettes/day.
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Table 11: Biomarker outcomes.a
VLNC vs CPD
(collapsed
across weeks 1
to 4)

Week
(collapsed
across
condition)

Condition x
Week
(interaction)

Condition x
Week
(controlling for
NRT patch
use)

Condition x
Week
(controlling for
percent nonstudy
cigarette/day)

Cotinine

8.3**

5.3***

7.7***

9.3**

2.3†

CO

4.9*

4.3**

3.3*

3.0*

1.6

F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CO=Carbon monoxide;
CPD=Condition that reduced cigarettes per day; NRT=Nicotine replacement therapy; VLNC=Condition
that switched to very low nicotine content cigarettes.
a
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Figure 12: Condition by week interaction predicts cotinine.
CPD=Condition that reduced cigarettes per day; ng/ml=Nanograms per milliliter; nic=Nicotine; VLNC=Condition that switched to very low nicotine
content cigarettes.
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Figure 13: Condition by week interaction predicts carbon monoxide (CO).
CPD=Condition that reduced cigarettes per day; nic=Nicotine; ppm=Parts per million; VLNC=Condition that switched to very low nicotine content
cigarettes.

3.5.1. Biomarker Outcomes Post-hoc Tests
Cotinine values for VLNC participants became significantly lower than CPD
participants at week 2 and remained lower for the rest of the study period (Table 12). In
contrast, CO was significantly lower for CPD than VLNC participants between weeks 1
through 3 only.
Table 12: VLNC vs CPD comparisons at each week: Biomarkers.a

Cotinine

Week 0
(100% nic)
0.2

Week 1
(70% nic)
0.3

Week 2
(35% nic)
4.8*

Week 3
(15% nic)
12.3**

Week 4
(3% nic)
20.3***

0.5
4.8*
6.3*
4.4*
0.6
CO
F values are reported; *p < 0.05; **p < 0.01; ***p < 0.001; CO=Carbon monoxide; CPD=Condition that
reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content
cigarettes; Only outcomes that had a significant condition by time interaction were tested at each week.
a

3.5.2. Biomarker Summary
Switching to VLNC cigarettes effectively reduced nicotine exposure (as
measured by cotinine). In contrast reducing CPD increased, not decreased, nicotine
exposure. Differences between VLNC and CPD participants’ cotinine became apparent at
week 2 when participants were instructed to reduce to 35% of their nicotine intake.
Smoke exposure (as measured by CO) decreased more for CPD than VLNC
participants. This difference was expected because the CPD reduction strategy required a
decrease in smoking while switching to VLNC cigarettes did not. Smoke exposure
decreased over time for both groups but decreased more for CPD participants. Post-hoc
comparisons indicate CPD participants had lower CO than VLNC participants only
during weeks 1 through 3.
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3.6. Quit Attempts and Cessation Measures
3.6.1. Self-Efficacy and Intention to Quit
I tested which reduction strategy increased self-efficacy (SEQ) and intention to
quit more and whether this increased over time. When collapsed across time, neither SEQ
nor intention to quit significantly differed between VLNC vs CPD conditions (Table 13).
When collapsed across conditions, intention to quit increased over time but there
was no significant change in self-efficacy. I also tested within-participant changes
separately among VLNC and CPD participants. Among VLNC participants, both selfefficacy (F=5.3, p<.01) and intention to quit (F=10.8, p<.001) increased over time.
Among CPD participants intention to quit increased over time (F=3.2, p<.05) but selfefficacy did not.
There was a significant condition by time interaction where self-efficacy to quit
increased over time for VLNC but not CPD participants (Figure 14). This effect remained
significant after controlling for NRT patch use but not when controlling for percent nonstudy cigarettes/day.
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Table 13: Self-efficacy and intention to quit.a
VLNC vs
CPD
(collapsed
across weeks
1 to 4)

Week
(collapsed
across
condition)

Condition x
Week
(interaction)

Condition x
Week
(controlling
for NRT
patch use)

Condition x
Week
(controlling
for percent
non-study
cigarette/day)

Self-Efficacy
to Quit (SEQ)

1

1.6

3.7**

4.0**

1.3

Intention-toQuit Ladder

3.2†

12.3***

1.3

1.1

2.3†

F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced
cigarettes per day; NRT=Nicotine replacement therapy; VLNC=Condition that switched to very low
nicotine content cigarettes.
a
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Figure 14: Condition by week interaction predicts self-efficacy to quit.
CPD=Condition that reduced cigarettes per day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes.

3.6.2. Self-Efficacy and Intention to Quit Post-hoc Tests
Self-efficacy to quit became significantly greater for VLNC than CPD
participants at week 4 (Table 14). Though the condition by week interaction was not
significant, intention to quit was also greater for VLNC than CPD participants at week 4
(F=6.2, p<.05).
Table 14: VLNC vs CPD comparisons at each week: Self-efficacy and intention to quit.a
Week 0
(100% nic)

Week 1
(70% nic)

Week 2
(35% nic)

Week 3
(15% nic)

Week 4
(3% nic)

Self-Efficacy
2.3
0
0
1.7
9.6**
to Quit
a
F values are reported; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced cigarettes per
day; nic=Nicotine; VLNC=Condition that switched to very low nicotine content cigarettes; Only outcomes
that had a significant condition by time interaction were tested at each week.

3.6.3. Plan to Quit, Quit Attempts, and Abstinence
In a series of logistic regressions I tested whether more VLNC vs CPD
participants made a plan to quit tomorrow, any QA (including very short attempts), and
≥ 24 hour QA. More participants in the CPD condition (41%) than VLNC condition
(17%) made any QA between weeks 1 through 4 (OR=3.3, 95% CI=1.04, 10.13).
Differences between the number of VLNC vs CPD participants who made a plan to quit
tomorrow (VLNC=56%, CPD=59%) or made a ≥ 24 hour QA (VLNC=19%,
CPD=16%) were not significant. One CPD participant and no VLNC participants were
7-day point-prevalence abstinent at the end of the study period.
In a series of survival analyses, I tested whether time to first plan to quit, any
QA (including very short attempts), and ≥ 24 hour QA differed between conditions
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from week 1 to 4. Time to first any QA was significantly shorter for the CPD than the
VLNC condition (Figure 15). This effect remained after controlling for NRT patch use
and percent non-study cigarettes/day throughout the study period (Table 15).
Table 15: Time to first plan to quit and quit attempt.a

a

Cox Hazard Ratio
(95% CI)

Cox Hazard Ratio
Adjusted for NRT
Patch Use
(95% CI)

Cox Hazard Ratio
Adjusted for Percent
Non-Study
Cigarettes/Day
(95% CI)

Plan to Quit

1.6 (0.8, 3.1)

1.7 (0.9, 3.2)

1.6 (0.8, 3.3)

Any QA

3.2 (1.2, 8.2)

3.1 (1.2, 8.1)

5.1 (1.5 17.7)

≥ 24 hour QA

1.9 (0.4, 3.7)

1.8 (0.4, 8.2)

1.9 (0.4, 8.3)

VLNC condition is the reference group; CI=Confidence interval; QA=Quit attempt.

I excluded QAs made during week 0 from my primary analyses because
reduction did not begin until week 1. Two CPD participants and no VLNC participants
made any QA and no participants made a ≥ 24 hour QA during week 0. Findings from
sensitivity analyses that included the two participants who made a QA during week 0
were similar to my primary findings reported above.
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Figure 15: Condition predicts time to first any quit attempt.
CPD=Condition that reduced cigarettes per day; QA=Quit attempt; VLNC=Condition that switched to very low nicotine content cigarettes.

3.6.4. Quit Attempts and Cessation Measures Summary
Overall, more CPD than VLNC participants made a QA that lasted any length of
time and there was a shorter time to first any QA among CPD than VLNC participants.
There were no significant differences between conditions in number of participants who
made a plan to quit tomorrow, number of participants who made a QA that lasted ≥ 24
hours, number of participants who were 7-day point prevalence abstinent, self-efficacy to
quit, or intention to quit. Intention to quit increased over time for both groups and selfefficacy increased for VLNC but not CPD participants.
3.7. One-Month Follow-Up Outcomes
3.7.1. Dependence, Self-Efficacy to Quit, and Intention to Quit at Follow-Up
See Appendix Table 1 for participants’ smoking characteristics at follow-up.
Forty (59%) participants responded to the follow-up survey. Missing data did not
significantly differ by condition. None of the dependence, self-efficacy, or intention to
quit measures significantly differed between VLNC vs CPD conditions at follow-up
(Table 16).
When collapsed across conditions, intention to quit decreased from week 4 to
the follow-up. I also tested within-participant changes separately among VLNC and CPD
participants. Among VLNC participants, intention to quit decreased from week 4 to
follow-up (F=4.4, p<.05) but there were no changes in dependence, cigarettes/day, or
self-efficacy. Among CPD participants, cigarettes/day increased from week 4 to follow-
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up (F=5.9, p<.05) but there were no changes in the dependence, self-efficacy, or intention
to quit measures.
There was a condition by time interaction where mean total cigarettes/day
increased in the CPD group but did not change significantly for the VLNC group from
week 4 to the follow-up (Figure 16). This effect remained significant after controlling for
NRT patch distribution and use during the follow-up period (Table 16).
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Table 16: One-month follow-up outcomes.a
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VLNC vs CPD
at Follow-Up

Time
(Week 4 to Follow-Up)

Condition x Time
(interaction)

Condition x Time
(controlling for
NRT patch use)

Total Cigarettes/Day

2.0

0.2

7.3**

6.7*

NDSS Overall Score

0.1

1.1

0.3

0.1

FTCD without
cigarettes/day

1.7

2.2

0.4

0.4

GN-SBQ

0.1

0

0.1

0.4

Addiction Ladder

0.9

3.4†

0

0.1

Self-Efficacy to Quit

0.1

3.5†

1.1

1.2

Intention-to-Quit Ladder

0.1

4.2*

0.7

0.6

F values are reported; †p < 0.1; *p < 0.05; **p < 0.01; ***p < 0.001; CPD=Condition that reduced cigarettes per day; FTCD=Fagerstrom test for
cigarette dependence; GN-SBQ=Glover-Nilsson Smoking Behavior Questionnaire; NDSS=Nicotine dependence syndrome scale; NRT=Nicotine
replacement therapy; VLNC=Condition that switched to very low nicotine content cigarettes.
a

18

16
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Figure 16: Condition by time interaction predicts change in total cigarettes/day from week 4 to follow up.
CPD=Condition that reduced cigarettes per day; VLNC=Condition that switched to very low nicotine content cigarettes.

3.7.2. Quit Attempts and Cessation at Follow-Up
Most participants set a quit date and requested NRT patches at their final study
visit (visit 4). There were no differences between VLNC vs CPD conditions in prolonged
abstinence, point-prevalence abstinence, or QAs at follow-up (Table 17).
Table 17: Quit attempts and cessation at follow-up.a
VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

Number completed
23 (64%)
17 (53%)
40 (59%)
follow-up survey
Number who set a quit date
18 (50%)
13 (41%)
31 (46%)
at final study visit (visit 4)
Number 30-day prolonged
5 (14%)
2 (6%)
7 (10%)
abstinent (PA)
Number 7-days point6 (17%)
4 (13%)
10 (15%)
prevalence abstinent (PPA)
Number made a
10 (28%)
4 (13%)
14 (21%)
QA ≥ 24 hours
Number made
16 (44%)
10 (31%)
26 (38%)
any QA
a
Percents are calculated from total sample of participants; CPD=Condition that reduced cigarettes per day;
QA=Quit attempt; VLNC=Condition that switched to very low nicotine content cigarettes.

3.7.3. Change from Pre-Study to Follow-Up
Among participants who responded to the follow-up survey (N=40), mean total
cigarettes/day decreased from 19.3 (SD=9.4) during the week prior to entering the study
(i.e., pre-study) to 13.9 (SD=9.0) at follow-up (F=6.0, p<.05). Mean self-efficacy to quit
(1=lowest, 5=highest) increased from 2.2 (SD=0.8) to 2.8 (SD=0.8; F=6.5, p<.05) and
mean intention to quit in the next 30 days (0=least, 10=most) increased from 3.6
(SD=3.1) to 5.2 (SD=3.3; F=4.6, p<.05). The degree to which participants smoked
menthol cigarettes (i.e., percent of cigarettes/day that are mentholated) did not change
over time or differ by condition. There were no significant condition by time interactions.
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3.8. Adverse Events
There were 70 moderate or mild adverse events (e.g., trouble sleeping) reported
on 38 of the 408 study visits. There were no serious adverse events (SAE) reported
during the study period or follow-up that could have plausibly been related to study
participation.
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CHAPTER 4: DISCUSSION
4.1. Summary of Findings
I encourage readers to refer to Table 18 for a full summary of my findings.
Briefly, switching to VLNC cigarettes was more acceptable than reducing CPD when
both were aided by NRT. Acceptability declined for CPD participants over time as they
were instructed to reduce down to 3% of their baseline nicotine. The equivalent reduction
remained acceptable for VLNC participants throughout the study period. Dependence
declined throughout the study period for both groups and appeared to decline more for
VLNC participants as they were instructed to reduce more nicotine. Biomarker findings
indicate that VLNC participants had less nicotine exposure (i.e., less cotinine) while CPD
participants had less smoke exposure (i.e., less CO). Intention to quit increased over time
for both groups while self-efficacy increased over time for VLNC but not CPD
participants. More participants in the CPD condition made any QA and they had a shorter
time to their first QA than VLNC participants.
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Table 18: Summary of findings.
Between-Participant
VLNC vs CPD

Within-Participant
VLNC
CPD
Primary Findings

Condition x Time

Acceptability:
Which strategy was more acceptable
and did this change over time?

VLNC > CPD
on 3 of 5 measures

-

↓ over time
on 3 of 5 measures

CPD ↓ over time and VLNC did not
on 3 of 5 measures

Dependence:
Which strategy decreased dependence
more and did this change over time?

-

↓ over time
on 5 of 5 measures
+ 1 subscale

↓ over time
on 4 of 5 measures
+ 1 subscale

VLNC ↓ more than CPD over time
on 2 of 5 measures + 1 subscale

Secondary Findings
Biomarkers:
Which strategy reduced biomarkers more and did this change over time?
CPD > VLNC

↓ over time

↑ over time

VLNC ↓ and CPD ↑ over time

Carbon monoxide (CO)

VLNC > CPD

↓ over time

↓ over time

CPD ↓ more than VLNC
at weeks 1, 2, and 3 only
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Cotinine

Quitting:
Which strategy increased measures of quitting more and did this change over time?
Self-efficacy to quit

-

↑ over time

-

VLNC ↑ over time and CPD did not

Intention to quit

-

↑ over time

↑ over time

-

Participants with a plan to quit
tomorrow

-

-

CPD > VLNC

CPD participants had a shorter time to first any QA

-

-

Participants with any QA
Participants with ≥ 24 hour QA

CPD=Condition instructed to reduce cigarettes/day; QA=Quit attempt; VLNC=Condition instructed to switch to very low nicotine content cigarettes.

4.2. Interpretation
Instructions to make large reductions in nicotine (i.e., 97%) were more
acceptable via switching to VLNC cigarettes than reducing CPD when both were aided
by NRT. Reducing CPD emerged as a less acceptable strategy than switching to VLNC
cigarettes only after instructions to reduce down to ≤ 35% of baseline nicotine. One
interpretation is that it was less acceptable for smokers to inhibit responses to cues to
smoke (i.e., reduce CPD) than to reduce the magnitude of the unconditioned reinforcer
(nicotine) without restricting their smoking behavior (i.e., switching to VLNC cigarettes).
Further, reducing the magnitude of the unconditioned reinforcer (i.e., nicotine) without
restricting responses to cues to smoke (i.e., switching to VLNC cigarettes) remained
acceptable throughout the study period. For example, VLNC participants’ non-study
cigarettes/day and willingness and ability to smoke study cigarettes did not significantly
change from ad-lib smoking at week 0 to smoking cigarettes with 3% nicotine content at
week 4.
Dependence declined over time for both groups despite the finding that cotinine
decreased for VLNC but not CPD participants. Thus, decreases in dependence do not
necessarily appear to be due to changes in the total amount of nicotine intake per se.
Instead, decreases in dependence could be due to changes in conditioning or smoking
behavior. VLNC participants could have decreased dependence by engaging in smoking
behavior with diminished unconditioned reward (i.e., less nicotine) and thus disrupting
operant and Pavlovian conditioning. CPD participants could have decreased dependence
by increasing practice not responding to cues to smoke (i.e., fewer cigarettes/day) and
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thus decreasing their frequency of exposure to conditioned and unconditioned reinforcers
from smoking. Though there is no prior research that suggests NRT per se decreases
dependence, NRT patch use could have contributed to a decrease in dependence in both
conditions. NRT could have helped to decrease dependence by providing a steady state of
nicotine independent of smoking and thus disrupting associations between cigarettes and
nicotine. The finding that decreases in dependence appeared greater for VLNC than CPD
participants could have been because reducing CPD became less acceptable and thus less
effective over time. This interpretation is supported by the finding that the time by
condition interaction was no longer significant on two of three measures of dependence
after controlling for percent non-study cigarettes/day (i.e., acceptability).
With regard to dependence, the condition by time interaction was most
pronounced on the NDSS Drive subscale (which assessed craving, withdrawal, and
compulsion to smoke) and remained significant after controlling for percent non-study
cigarettes/day. This finding appears consistent with animal research that suggests
extinction occurs when an organism responds to stimulus cues in the absence of a
reinforcer (i.e., smoking without nicotine) but not when prevented from responding to
cues (i.e., not smoking) (Bouton, Trask, & Carranza-Jasso, 2016). In other words, by
smoking cigarettes with low nicotine, VLNC participants could have learned that
smoking in response to stimulus cues was associated with less pharmacological reward
(nicotine) and thus experienced a decrease in the drive to smoke. In contrast, CPD
participants could have learned to resist the drive to smoke in response to stimulus cues
with less actual change in the drive to smoke per se. However, differences between
VLNC and CPD participants were not significant on multiple secondary measures of
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dependence. It is particularly surprising that there were no between group differences on
the dependence scales that focus on behavioral aspects of dependence (e.g., the GN-SBQ,
or the NDSS Continuity and Stereotypy subscales) because the CPD reduction strategy
targeted change in smoking behavior while the VLNC strategy did not.
Cotinine decreased for VLNC participants but unexpectedly increased for CPD
participants over time. Thus, when both were aided by NRT, switching to VLNC
cigarettes was effective at reducing overall nicotine exposure, but reducing CPD was not.
Importantly, the increase in cotinine among CPD participants conflicts with prior findings
(Hughes & Carpenter, 2005) and thus requires replication and should be interpreted with
caution. One potential explanation for this finding could be that a combination of NRT
use and compensatory smoking (i.e., smoking remaining cigarettes more vigorously)
could have contributed to an increase in nicotine exposure despite CPD participants’
reduction (mean 60%) in total cigarettes/day. A prior study estimated that daily NRT
patch use provides approximately 50% of the nicotine that would be obtained from heavy
smoking (Hurt et al., 1993). In this trial, NRT’s influence on cotinine levels is supported
by the observation that cotinine appears to have increased from week 0 to week 1 for both
groups (see Figure 12) when participants began using NRT patches. However,
differences between VLNC vs CPD participants’ cotinine over weeks 0 to 4 remained
after controlling for NRT, and NRT use did not differ between groups. Thus differences
between VLNC and CPD participants’ nicotine exposure appear to be due to more than
NRT use per se. With regard to compensatory smoking, a prior review (Hughes &
Carpenter, 2005) estimated that 33% compensation occurs when reducing CPD with the
aid of NRT, but found compensation as high as 64% in some cases (Rennard et al., 1994).
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In my trial, CO (another biomarker used to assess compensatory smoking) decreased for
CPD participants over time which suggests that, while some compensation likely
occurred, it was not enough to offset all biomarkers. Thus, though changes in cotinine
were likely influenced by a combination of NRT use plus some compensatory smoking, it
is unclear why cotinine decreased for VLNC but increased for CPD participants over
time.
Both VLNC and CPD participants reduced CO over time. However, CPD
participants had greater reductions in CO. This is not surprising given that CPD
participants were instructed to reduce their smoking while VLNC participants were not.
The reduction in CO reflects CPD participants’ mean 60% reduction in total
cigarettes/day. VLNC participants’ reduction in CO reflects their mean 19% reduction in
total cigarettes/day and suggests that NRT-aided transitions to VLNC cigarettes also
prompts a reduction in smoke exposure despite no instructions to reduce cigarettes/day.
Further, VLNC participants’ reductions in CO supports a prior review on compensatory
smoking (Hatsukami et al., 2015) and suggests gradual transitions to VLNC cigarettes do
not result in compensation when aided by NRT. Differences in CO between CPD and
VLNC participants diminished at week 4. This could be due to an increase in CPD
participants’ non-study cigarettes, a decrease in VLNC participants’ total cigarettes/day,
or both.
Importantly, neither condition by time interaction for cotinine or CO was
significant after controlling for percent non-study cigarettes/day (i.e., acceptability).
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Thus, differences in nicotine and smoke exposure were likely influenced by differences
in acceptability.
Another unexpected finding was that self-efficacy to quit increased in the VLNC
and not CPD group, but more CPD than VLNC participants attempted to quit. One
explanation for the self-efficacy finding is that, despite substantial reductions in
cigarettes/day (i.e., 60%), most CPD participants’ did not achieve the trial’s large
reduction goals (i.e., 97%). Thus, the failure to achieve study goals may have served as a
barrier to building self-efficacy to quit. Quitting requires not smoking in response to
environmental or internal cues. Thus, the fact that CPD participants had more practice not
smoking in the presence of cues to smoke could have prompted them to make more QAs
than VLNC participants. Condition’s effect on making any QA remained after controlling
for percent non-study cigarettes/day, which suggests findings were not due to differences
in acceptability. It is unclear why the CPD intervention increased QAs but not selfefficacy to quit. Further, there were no between-group differences in ≥ 24 hour QAs or
longer periods of abstinence. This could be because factors that influence quit attempts
differ from those that influence ability to remain abstinence (Vangeli, Stapleton, Smit,
Borland, & West, 2011).
At follow-up, there was a time by condition interaction in which total
cigarettes/day did not significantly change for VLNC participants but increased for CPD
participants from week 4 to follow-up. One interpretation is that VLNC participants
reverted to comfortable levels of nicotine intake while CPD participants reverted to
comfortable frequencies of smoking behavior. VLNC participants who continued to
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smoke after the study period had to switch from study cigarettes with 3% nicotine to full
nicotine commercial cigarettes because VLNC cigarettes are not commercially available.
Thus, it is likely that VLNC participants increased their nicotine intake to levels more
similar to baseline despite a non-significant decrease in number of cigarettes/day from
week 4 to follow-up. CPD participants significantly increased their smoking from a mean
8.5 cigarettes/day (40% of baseline) to 16.5 cigarettes/day (78% of baseline). Thus CPD
participants appeared to have reverted to smoking behavior more similar to baseline.
4.3. Comparison to Prior Reduction Studies
This is the first trial to directly compare switching to VLNC cigarettes vs
reducing CPD. Thus, comparison to prior studies is limited to my within-participant
findings in the VLNC and CPD conditions. In terms of VLNC cigarettes’ acceptability,
one prior trial of gradual transitions reported participants smoked a mean 20% non-study
cigarettes/day when they were instructed to switch to VLNC cigarettes with 0.6 mg/g
nicotine (Hammond & O'Connor, 2014). Similarly, in the present study participants
smoked a mean 21% non-study cigarettes/day when they were instructed to smoke study
cigarettes containing 0.4 mg/g nicotine. My finding that dependence decreased over time
among participants who switch to VLNC cigarettes is consistent with the four prior trials
of progressive transitions to VLNC cigarettes that measured dependence (Benowitz et al.,
2009, 2012; Benowitz et al., 2007; Hammond & O'Connor, 2014). In terms of
biomarkers, my findings replicated results from the five prior VLNC trials that measured
change in cotinine: all found significant declines as participants transitioned to
progressively lower nicotine content cigarettes (Benowitz et al., 2009, 2012; Benowitz et
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al., 2007; Hammond & O'Connor, 2014; Mercincavage et al., 2016). In contrast to my
finding that CO declined for VLNC participants, two prior trials found small increases in
CO (Benowitz et al., 2012; Mercincavage et al., 2016) and one found no change
(Hammond & O'Connor, 2014) over time. Differences may have been due to the fact that
I provided NRT, which likely decreased compensatory smoking, but the prior trials did
not. In terms of self-efficacy to quit, my results were consistent with two trials’ findings
that switching to VLNC cigarettes increased self-efficacy (Benowitz et al., 2009;
Benowitz et al., 2007). However a third trial of switching to progressively lower nicotine
VLNC cigarettes did not find changes in self-efficacy (Benowitz et al., 2012). No prior
trials of gradual transitions to VLNC cigarettes reported on intention to quit or QAs. Two
studies found that 24% (Benowitz et al., 2007) and 10% (Benowitz et al., 2009) of
participants achieved point-prevalence abstinence at a 30-day follow-up. In my trial 17%
of VLNC participants achieved 7-day point-prevalence abstinence and 14% achieved 30day prolonged abstinence at the 1-month follow-up.
Comparison between the CPD condition in my trial and prior trials of reduction
in CPD are limited due to multiple methodological differences. For example, I set a large
reduction goal for CPD participants to be comparable to equivalent reductions in nicotine
using VLNC cigarettes. In contrast, prior trials either set smaller (e.g., 50% reduction) or
no reduction goals. Acceptability was not directly measured in prior reduction trials. CPD
participants in my trial reduced more total cigarettes/day (60%) than most (Hughes, 2000;
Hughes & Carpenter, 2005) but not all (Stein et al., 2002) prior NRT-aided reduction
trials for smokers not ready to quit. My finding that CPD participants decreased
dependence over time is consistent with all four of the prior reduction studies that
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measured dependence (Etter et al., 2002; Fagerstrom et al., 2002; Klemperer et al., 2015;
Mooney et al., 2011). In terms of biomarkers, my finding that cotinine increased over
time conflicts with findings from a prior review (Hughes & Carpenter, 2005) and thus
requires replication. In contrast, my finding that CO decreased over time is consistent
with conclusions from the same review (Hughes & Carpenter, 2005). In terms of selfefficacy and intention to quit, two prior trials found that interventions to reduce CPD
resulted in increases in both (Carpenter et al., 2004; Klemperer et al., 2017). In this trial, I
used the same measures and found that intention to quit increased among CPD
participants but self-efficacy did not. One explanation for differences in self-efficacy is
that prior trials instructed participants to set achievable goals to reduce CPD with the
rationale that this could enhance self-efficacy to quit (Carpenter et al., 2004; Klemperer
et al., 2017). As previously discussed, I set a very ambitious reduction goal for
participants, which the majority of participants did not achieve.
Two prior trials tested CPD reduction interventions and found 47% and 54%
made any QA and 31% and 43% made a QA that lasted ≥ 24 hours over the course of 6
months (Carpenter et al., 2004; Klemperer, Hughes, Solomon, Callas, & Fingar, 2016). In
contrast, I assessed quitting over a 1-month period and found fewer made any QA (41%)
or a QA that lasted ≥ 24 hours (16%). Differences are likely due to the fact that my trial
measured quitting over a shorter duration than prior trials. Trials included in prior
reviews on NRT-aided reduction for smokers not ready to quit varied in treatment length
and duration of follow-up and found a range of abstinence from 1% to 35% (Asfar et al.,
2011; Hughes & Carpenter, 2006; Moore et al., 2009; Wu et al., 2015). The trial that was
most similar to mine in duration (1 month) found 5% of participants quit at some point
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during the study period and 2% were abstinent at a 1-month follow-up (Fagerstrom,
Tejding, Ake, & Lunell, 1997). In my study 13% of CPD participants were 7-day pointprevalence abstinent and 6% achieved 30-day prolonged abstinence at the 1-month
follow-up.
4.4. Implications
4.4.1. Policy Implications
My findings suggest that a policy to reduce cigarettes’ nicotine content could
provide smokers not ready to quit with a more acceptable and effective strategy to reduce
nicotine intake than the commonly used strategy of reducing CPD. Moreover such a
policy could also provide smokers with a more effective strategy to reduce dependence.
Importantly, it is unclear whether future tobacco regulation will require abrupt switching
to the lowest level VLNC cigarettes or allow for a gradual transition to VLNC cigarettes
with progressively less nicotine. My within-participant findings for the VLNC condition
suggest that policies that allow for or require gradual transitions to VLNC cigarettes
could provide an acceptable strategy for smokers not ready to quit to decrease
dependence, cotinine, and CO and increase self-efficacy and intention to quit. However,
my findings and others’ (Donny et al., 2015) demonstrate that the greatest reductions in
dependence and biomarkers are achieved at the lowest level nicotine cigarettes. Thus, if
feasible, a policy requiring abrupt transitions to the lowest level VLNC cigarettes is likely
to result in the most rapid benefit to smokers.
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Policies that promote reduction in CPD could also provide benefits to smokers
not ready to quit. For example, reducing CPD decreased CO and increased QAs more
than switching to VLNC cigarettes in my study. Future research is needed to test the
degree to which policy that promotes the combination of switching to VLNC cigarettes
plus reducing CPD would provide benefit beyond a policy that promotes one or the other.
Importantly, I provided NRT and instructed participants to follow a weekly schedule and
make large reductions over a relatively short period of time. Thus, my findings are
limited in the extent to which they apply to the likely slower reduction that would occur
in response to tobacco regulation policies.
4.4.2. Clinical Implications
Within-participant changes from switching to VLNC cigarettes and reducing
CPD appear clinically meaningful when both strategies are aided by NRT. With regard to
dependence, mean NDSS Overall Scores decreased by 0.94 units for VLNC and 0.47 for
CPD participants. A one unit decrease in NDSS Overall Score in my prior 1-month
reduction trial among smokers not ready to quit predicted a 62% increase in the odds of
attempting to quit and a 54% increase in the odds of 7-day point prevalence abstinence 6
months later (Klemperer et al., 2017). With regard to biomarkers, VLNC participants in
this trial decreased cotinine by a mean 42% and CO by 20%. CPD participants increased
cotinine by a mean 20% and decreased CO by a mean 27%. Prior reduction trials found
greater decreases in cotinine predicted cessation at a 6-week follow-up (Dermody,
Donny, Hertsgaard, & Hatsukami, 2014) and greater decreases in CO predicted cessation
at a 13-week follow-up (Rose, Behm, & Westman, 1998), though the magnitudes of these
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effects were not clear. In this trial, self-efficacy to quit increased by a mean one unit for
VLNC participants but did not significantly change for CPD participants. A one unit
increase in the same self-efficacy scale predicted a 54% increase in the odds of making a
QA over the next 6 months but did not predict cessation in my prior reduction trial
(Klemperer et al., 2017). In this trial, mean intention to quit increased by 3.2 units for
VLNC participants and 1.5 for CPD participants. A one unit increase in the same
intention to quit scale predicted a 35% increase in the odds of making a QA and a 35%
increase in the odds of 7-day point prevalence abstinence 6 months later in my prior trial
(Klemperer et al., 2017).
Clinical interventions for smokers not ready to quit will likely need to be
adapted when the FDA regulates cigarettes’ nicotine content. In my trial, a structured 4week NRT-aided transition to VLNC cigarettes was an acceptable strategy that produced
clinically meaningful decreases in dependence and biomarkers and increases in selfefficacy and intention to quit. Thus, progressively reducing to lower nicotine content
cigarettes with the aid of NRT could be an important component of future interventions
for smokers not ready to quit. However, my secondary findings demonstrate that reducing
CPD increased initial attempts to quit and decreased CO more than switching to VLNC
cigarettes. Thus, future research should examine whether the benefits of switching to
VLNC cigarettes and reducing CPD can be achieved with the same intervention. Further,
though widely available, NRT is used infrequently (Shiffman, Brockwell, Pillitteri, &
Gitchell, 2008). In contrast, alternative nicotine delivery systems such as e-cigarettes may
be a more acceptable way to supplement nicotine intake in future interventions to
facilitate reduction in nicotine from combustible cigarettes.
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My findings also demonstrate that, with the aid of NRT, large reductions in
nicotine, cigarettes/day, and dependence are possible among smokers not ready to quit. I
instructed participants to reduce most of their nicotine over a short period of time because
this appeared effective in prior VLNC studies (Benowitz et al., 2009; Benowitz et al.,
2007) and it was unclear whether the equivalent reduction in CPD was feasible. VLNC
participants achieved substantial nicotine reductions and CPD participants achieved
substantial reductions in cigarettes/day over a 4 week period with the aid of NRT. Thus
ambitious reduction goals appear feasible among smokers not ready to quit. I also found
convergent validity demonstrating that reductions in dependence are feasible over a
relatively short period of time. Nicotine dependence is often measured as a participant
characteristic at baseline. However, my findings support prior prospective trials that
found within participant change in dependence (Benowitz et al., 2012; Fagerstrom et al.,
2002) and suggest that reducing dependence is a feasible short-term goal for interventions
targeting smokers not ready to quit.
4.4.3. Behavioral Implications
Broadly, my findings indicate that reducing the magnitude of an unconditioned
reinforcer (e.g., switching to VLNC cigarettes) could be a more acceptable strategy to
promote behavior change than restricting responses to stimulus cues (e.g., reducing
CPD). Differences between the strategies’ influence on behavior change could be due to
differences in learning. As previously discussed (see Figure 1 and Figure 2 in section
1.1), reducing the magnitude of an unconditioned reinforcer could promote extinction by
disrupting associations between 1) a response behavior and unconditioned reinforcer, 2)
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stimulus cues and a response behavior, and 3) conditioned and unconditioned reinforcers.
In contrast, restricting behavior in response to stimulus cues provides increased practice
with response inhibition and decreased exposure to unconditioned and conditioned
reinforcers but may not promote extinction per se. My finding that switching to VLNC
cigarettes appeared to decrease dependence more than reducing CPD supports the theory
that reducing the magnitude of an unconditioned reinforcer promotes extinction more
than restricting behavioral responses to stimulus cues. Nonetheless, the fact that more
CPD participants made a QA suggests that increased practice restricting behavior in
response to stimulus cues may promote initial, but not necessarily sustained, behavior
change. Future research is needed to examine the extent to which findings from this study
can be applied to behavior change in humans beyond cigarette smoking.
4.5. Limitations and Assets
4.5.1. Limitations
As previously mentioned, one limitation is that all study cigarettes were
mentholated because of the limited cigarettes available to us from NIDA. Thus we block
randomized so that the proportion of menthol to non-menthol smokers was similar
between groups. This may have been less of a problem because all study cigarettes were
novel. In addition subjective evaluation of cigarettes did not differ between groups or
between participants that identified as menthol vs non-menthol smokers before entering
the study. Whether participants identified as menthol smokers or not before entering the
study did not moderate any outcomes. Finally, there was no difference in the amount of
menthol cigarettes smoked before entering the study vs during the follow-up period.
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Due to limited funding, this study did not include a control condition (i.e., a group
that smoked as usual for the entire study period). Thus I used within-participant
comparisons to examine the effectiveness of reduction strategies compared to
participants’ ad-lib smoking during week 0. Secondary findings measured at follow-up
were also limited because 41% of participants were missing at the 1-month follow-up.
Further, after the study period, participants in the CPD condition could continue smoking
fewer cigarettes but those in the VLNC condition could not continue smoking VLNC
cigarettes because they are not commercially available in the US.
Another limitation is that I was unable to biochemically verify compliance with
instructions to only use study cigarettes and not usual brand cigarettes. Biochemical
estimation of compliance was not possible because participants used NRT and most study
cigarettes contained too much nicotine to detect non-compliance (Benowitz, 2015). In
order to increase the validity of participants’ self-report, I 1) informed participants that
self-reported noncompliance does not influence their payment or future participation and
2) employed a bogus pipeline technique that has been used in multiple prior studies
(Aguinis et al., 1993). Prior studies have found discrepancies between self-report and
biochemical estimations of compliance (Nardone et al., 2016). Thus the percent nonstudy cigarettes/day was likely higher in both groups, though I have no reason to believe
that discrepancies between actual and self-reported non-study cigarettes/day differed
between groups.
I instructed participants to reduce most of their nicotine over a short period of
time to compare transitions to VLNC cigarettes to equivalent reductions in CPD.
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Importantly, clinical interventions to reduce CPD often provide smaller goals or no goals
at all. My prior studies found dose response relationships where greater magnitudes of
reduction were associated with greater decreases in dependence (Klemperer et al., 2015)
and increases in QAs (Klemperer, Hughes, & Naud, 2018) and cessation (Klemperer &
Hughes, 2016). Thus, the overall effects of reduction on dependence and quitting would
likely be smaller among smokers who reduced less. Prior studies suggest that switching
to VLNC cigarettes may be most impactful at the lowest level of nicotine (i.e., 3%)
(Donny et al., 2015). Thus, while it was more internally valid to compare equivalent
reductions between VLNC and CPD conditions, VLNC participants may have
experienced more clinically meaningful changes had they smoked the lowest level
cigarettes for more than 1 week.
I conducted analyses to examine 22 outcomes which increased the probability of
false positives. However I did not include p value corrections because, like many
statisticians, I am concerned that these adjustments are based on arbitrary cutoffs and
increase the probability of type II errors (Feise, 2002). I limited my moderator analyses to
gender and menthol status. However, this study was underpowered to detect moderator
effects which could be one reason why my moderator analyses were not significant.
I used a convenience sample and inclusion criteria that may have limited the
generalizability of my findings. Participants in my study were less diverse and had more
years of education than a nationally representative sample of smokers (Hughes & Callas,
2010). Further, because blinding participants to the number of cigarettes they smoke was
not possible, neither participants nor researchers in my study were blind to condition.
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Awareness of switching to VLNC cigarettes or reducing CPD may have influenced
outcomes. Finally, participants’ nightly responses to surveys about their smoking may
have influenced their smoking (McCarthy, Minami, Yeh, & Bold, 2015).
4.5.2. Assets
This randomized trial is the first to directly compare the FDA proposed strategy
to switch to VLNC cigarettes vs the commonly used strategy of reducing CPD.
Participants in both groups were instructed to use different strategies to attempt to reduce
a similar amount of nicotine. This comparison also provided an opportunity to examine
the influence of reducing the magnitude of an unconditioned reinforcer (VLNC
condition) vs restricting behavior in response to stimulus cues (CPD condition) in
humans. Most smokers are not ready to quit in the near future but few interventions are
designed for this population (PROPEL Centre for Population Health Impact, 2015).
Importantly, this trial compared two reduction strategies that can be used to design or
improve clinical interventions for smokers not ready to quit. In addition to between-group
comparisons, this trial made within-participant comparisons, which is a more valid test of
behavior change (Sidman, 1960). I collected data weekly and nightly to minimize recall
bias (Shiffman, 2009). There was a relatively low rate of missing data (9%) and dropouts
(7%). In addition, I used an adequate sample size to detect changes in nicotine
dependence and included multiple measures to assess convergent validity for both of my
primary outcomes. Finally, findings from this study contribute to the science of nicotine
addiction on a theoretical, clinical, and policy level.
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4.6. Future Research
Future research is needed to replicate and expand on findings from my
dissertation as they relate to behavioral, clinical, and regulatory sciences. A laboratory
study to test the degree to which reducing the magnitude of unconditioned reward from
drug use vs restricting response to stimulus cues disrupts behavioral conditioning could
inform basic understanding of drug dependence in humans. My finding that dependence
decreased despite an increase in nicotine exposure among CPD participants was
unexpected and thus future research is needed to replicate this effect and examine the
influence of behavior change vs nicotine intake on dependence. Further, research testing
the reduction strategies in this trial in combination with existing interventions could
inform clinicians on how to treat smokers not ready to quit when VLNC cigarettes are
commercially available in the US. Finally, a pragmatic trial to compare switching to
VLNC cigarettes vs reducing CPD in a less structured “real world” context could be
useful to inform future tobacco regulation policy.
4.7. Conclusions
This is the first trial to compare the FDA proposed strategy of switching to
VLNC cigarettes vs the commonly used strategy of reducing CPD. Both reduction
strategies were aided by NRT. Broadly, there are two main conclusions from my
dissertation. First, reducing was more acceptable when switching to cigarettes with
progressively less nicotine (VLNC cigarettes) than when progressively reducing the
number of CPD. Second, though both reduction strategies decreased dependence over
time, switching to VLNC cigarettes appeared to decrease dependence more than reducing
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CPD. Thus, when both are aided by NRT, switching to VLNC cigarettes appears to be a
more superior reduction strategy than reducing CPD for smokers not ready to quit.
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5. APPENDIX
Appendix Table 1: Week 0, week 4, and follow-up smoking characteristics.a

VLNC
(n=36)

Week 0
CPD
(n=32)

Total
(N=68)

Mean total cigarettes/day

20.1
(8.8)

21.1
(12.2)

Mean percent non-study cigarettes/day

7.1
(16.9)

110

Median percent non-study
cigarettes/day
Mean willingness to smoke
type of cigarette
(1=least, 5=most)
Mean ability to smoke
type of cigarette
(1=least, 5=most)
Mean willingness to smoke
number of cigarettes
(1=least, 5=most)
Mean ability to smoke
number of cigarettes
(1=least, 5=most)
Mean Nicotine Dependence Syndrome
Scale, Overall Score (NDSS-OS)
Mean Fagerstrom Test for Cigarette
Dependence (FTCD; excluding
cigarettes/day;
0=lowest, 7=highest)
Mean Glover-Nilsson Behavioral
Dependence Questionnaire (GN-SBQ;
0=lowest, 44=highest)

VLNC
(n=36)

Week 4
CPD
(n=32)

Follow-Up
CPD
Total
(n=17)
(N=40)

Total
(N=68)

VLNC
(n=23)

20.6
(10.5)

16.2
(9.8)

8.5
(6.9)

12.6
(9.3)

11.9
(7.7)

16.5
(10.2)

13.9
(9.0)

7.4
(11.5)

7.2
(14.5)

21.4
(36.5)

72.1
(33.9)

44.5
(43.4)

-

-

-

1.5

0.1

1.2

0

86.2

22

-

-

-

4.3
(1.1)

4.4
(0.9)

4.4
(1.0)

4.1
(1.5)

4.3
(0.9)

4.2
(1.2)

-

-

-

4.1
(1.2)

4.1
(1.1)

4.1
(1.2)

4.2
(1.3)

4.0
(1.0)

4.1
(1.2)

-

-

-

4.3
(1.1)

4.2
(1.0)

4.2
(1.1)

4.4
(1.2)

2.9
(1.4)

3.7
(1.5)

-

-

-

4.1
(1.3)

3.8
(1.1)

3.9
(1.2)

4.1
(1.3)

2.7
(1.3)

3.5
(1.5)

-

-

-

-0.70
(.85)m,

-0.77
(0.92)

-0.73
(0.88)

-1.64
(0.83)

-1.24
(0.88)

-1.45
(0.9)

-1.45
(0.84)

-1.35
(0.72)

-1.41
(0.78)

3.1
(1.4)

3.0
(1.5)

3.0
(1.5)

2.3
(1.7)

2.6
(1.7)

2.4
(1.7)

2.5
(1.5)

3.3
(1.7)

2.9
(1.6)

15.7
(6.5)

16.1
(6.6)

15.9
(6.5)

10.5
(8.2)

11.1
(6.8)

10.8
(7.5)

9.8
(8.2)

10.4
(4.8)

10.1
(6.9)

Week 0

Week 4

Follow-Up

VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

VLNC
(n=36)

CPD
(n=32)

Total
(N=68)

VLNC
(n=23)

CPD
(n=17)

Total
(N=40)

Mean Addiction Ladder
(0=lowest, 10=highest)

8.6
(1.9)

8.9
(1.2)

8.7
(1.6)

5.5
(3.3)

6.7
(2.7)

6.0
(3.1)

6.8
(3.0)

7.9
(2.9)

7.3
(2.9)

Mean time to first cigarette (TTFC) in
minutes

24.8
(20.2)

24.0
(23.0)

24.4
(21.4)

42.6
(36.4)

46.4
(43.7)

44.3
(39.6)

-

-

-

Mean self-efficacy to quit
(SEQ; 1=lowest, 5=highest)

2.4
(1.1)

2.9
(1.0)

2.7
(1.0)

3.4
(1.1)

2.5
(1.0)

3.0
(1.1)

2.7
(0.8)

2.8
(0.8)

2.8
(0.8)

Mean Intention-to-Quit Ladder
(0=lowest, 10=highest)

4.5
(3.5)

4.0
(3.5)

4.3
(3.5)

7.7
(3.1)

5.5
(3.5)

6.7
(3.4)

5.4
(3.4)

5.1
(3.3)

5.2
(3.3)

1,327.1
(665.2)

1,266.7
(567.2)

1,298.3
(616.5)

769.4
(571.5)

1,537.4
(658.4)

1,123.9
(719.6)

-

-

-

Mean cotinine ng/ml

24.9
22.5
23.8
19.9
16.5
18.3
(14.0)
(12.1)
(13.1)
(17.6)
(11.9)
(15.1)
a
Standard deviations in parentheses; CPD=Condition that reduced cigarettes per day; ng/ml=Nano grams per milliliter; ppm=Parts per million;
VLNC=Condition that switched to very low nicotine content cigarettes.
Mean carbon monoxide (CO) ppm

-
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